Vorinostat (SAHA, MK0683)

製品コードS1047 別名：SAHA, MK0683, suberoylanilide hydroxamic acid

Vorinostat (SAHA, MK0683)化学構造

分子量(MW)：264.3

Vorinostat (suberoylanilide hydroxamic acid, SAHA) is an HDAC inhibitor with IC50 of ~10 nM in a cell-free assay.

サイズ 価格(税別)  
JPY 31706.00
JPY 24402.00
JPY 36520.00
お問い合わせ バルク問合せ

文献中Selleckの製品使用例(103)

カスタマーフィードバック(20)

  • Activity of vorinostat in Jurkat and Peer T-ALL cell lines in an MTT cell viability assay. Cells were treated with increasing drug concentrations for 72 h. The data are plotted as the mean % of DMSO-treated control cells against the corresponding drug concentration. The error bars are the standard error. For each drug and cell line, 3-4 independent experiments were performed with 6 replicates at each drug concentration.

    Nature 2011 471, 235-9. Vorinostat (SAHA, MK0683) purchased from Selleck.

    Differential effects of HDAC inhibitors on histone and tubulin acetylation. Immunofluorescence analysis of histone H3 (K9ac/K14ac) and tubulin acetylation in HeLa cells treated for 4 h with vehicle, SAHA (10 μM), tacedinaline (50 μM), PCI-24781 (20 μM. (a) Mapping of histone acetylation in K562 cells treated with HDAC inhibitors by LC-MS/MS. Cells were treated with TSA (10 μM), SAHA (5 μM), PCI-24781 (2 μM), tacedinaline (50 μM) for 6 h. Histones were extracted from cells and acetylated peptides were quantified after isobaric tagging.

    Nat Biotechnol 2011 29, 255-265. Vorinostat (SAHA, MK0683) purchased from Selleck.

  • Western blot analysis of histone H3 acetylation in the spleen of untreated and vorinostat-treated hNF-E2 tg mice (n = 4 of each genotype).

    J Exp Med 2012 209, 35-50. Vorinostat (SAHA, MK0683) purchased from Selleck.

    SAHA down-regulates c-FLIP expression and increases the sensitivity of CaP cells to undergo apoptosis in the presence of bicalutamide (A) Bar graph illustrating the sub-G0/G1 cell population in 22Rv1 (left panel) and LNCaP (right panel) cells in the absence and presence of 10μM bicalutamide, administered as a single agent or in ombination with increasing concentrations of the HDAC inhibitor, SAHA. (B) Immunoblots demonstrating the single agent activity of bicalutamide or SAHA, or effect upon their combined administration on the expression of c-FLIP and/or the processing of PARP. Equal protein loading was confirmed by GAPDH. (C) Bar graph illustrating the effect of bicalutamide and SAHA upon the induction of caspase-8 or caspase-3/7 activity in 22Rv1 cells (left panel) and LNCaP cells (right panel). (D) Immunoblots characterizing the impact of SAHA and/or bicalutamide upon the induction of PARP cleavage, in the absence or presence of the pan-caspase inhibitor, ZIETD. ZIETD was incubated with the cells for 12 h prior to the experiment. All data points shown in (A) and (C) represent the mean ± S.E.M. value, calculated from four independent experiments.

    Clin Cancer Res 2012 18, 3822-33. Vorinostat (SAHA, MK0683) purchased from Selleck.

  • Analyses of efficacy, potency and IC50 of HDAC inhibitors point toward HDACs 1–3 as relevant candidates for beta cell protection. Ranking and raw data on ITF drugs (Table 3) and commercial HDAC inhibitors (Table 4) underlying the heat maps of Fig. 1 (A and B). The HDAC inhibitor compounds were tested using a HDAC activity kit and recombinant proteins to determine IC50 values on each individual HDAC (right part of the table). Each drug was further tested using Real-Time Cell Analysis (RTCA) to score their maximal effective concentration (ECmax) as well as the corresponding rescue percentage of cytokine treated INS-1 cells. The drugs were ranked according to % rescue. * DMSO alone controls were included in each experiment, but not shown here. The results indicate that the highest concentrations of DMSO used here (1:1,000) were slightly potentiating the proliferation of the cells. The effects observed in this group of compounds were ascribed to the DMSO.?

    Diabetologia 2012 55, 2421-2431. Vorinostat (SAHA, MK0683) purchased from Selleck.

    Suberoylanilide hydroxyamic acid (SAHA) preserves CFP (+) expression in mouse optic nerves (MONs) from older mice. (a) CFP (+) mitochondria were longer and thicker in MONs from 12-month-old Thy-1 CFP mice (inset; scale bar = 2 μm). Oxygen–glucose deprivation (OGD) consistently reduced CFP pixel intensity in 12-month-old MONs despite longer and brighter CFP ( +) mitochondria (yellow arrows). (b) Blockade of AMPA/kain ate receptors with NBQX (30 μM), or pan-Histone deacetylase (HDAC) inhibition with SAHA (5 μM), effectively preserved CFP pixel intensity during OGD. The preservation of CFP (+) mitochondria correlates with protection of the CAP area during OGD and profound recovery.

    J Neurochem 2012 123 Suppl 2, 108-15. Vorinostat (SAHA, MK0683) purchased from Selleck.

  • D and E, Regression of IL-13Ra 2-negative pancreatic tumors treated with SAHA and/or IL-13-PE. Mice were treated daily with i.p. injection of SAHA (25 mg/kg) from day 4 after tumor implantation for two weeks followed by i.t. injection of IL-13-PE (100 μ g/kg) from day 5 for two weeks. F and G, Regression of IL-13Ra 2-posotive pancreatic tumors (HS766T and MIA-PaCa2) treated with SAHA and/or IL-13-PE. The schedule of treatment was similar as in panel D and E. Statistical significances are shown by *: P < 0.05,†: P < 0.001.

    J Transl Med 2011 9, 37. Vorinostat (SAHA, MK0683) purchased from Selleck.

    IL-13Rα2 expression is upregulated in pancreatic tumors but not in organs of mice after treatment with HDAC inhibi tor, SAHA. A, qRT-PCR of human IL-13Rα2 in implanted pancreatic tumors after SAHA and IL-13-PE treatment. Tumors were harvested next day after IL-13-PE treatment and total RNA extracted. Data shown is ratio of human IL-13Rα2/β-actin expression and multiplied by 1000 for convenience. Bars , SD of triplicate determinations. B, qRT-PCR of mouse IL-13Rα2 in mice organs after SAHA and IL-13-PE treatment. Tissues were harvested at the same time point as in panel A and total RNA extracted. Data shown is ratio of mouse IL-13Rα2/β-actin expression and multiplied by 100 for convenience. C, IHC of human IL-13Rα2 in implanted pancreatic tumors after SAHA and IL-13-PE treatment. D, IHC of mouse IL-13Rα2 in mice organs after SAHA and IL-13-PE treatment. Liver, brain, kidney, pancreas, lung and spleen were fixed for immunostaining of mouse IL-13Rα2 as visualized by Alexa555. Nucleus was counterstained by DAPI.

    J Transl Med 2011 9, 37. Vorinostat (SAHA, MK0683) purchased from Selleck.

  • Proliferation o f HT29 and HCT116 cells after 48 h of butyrate or SAHA treatment. Proliferation measurements using the xCEL Ligence RTCA DP instrument (Roche) in cells treated with increasing doses of butyrate or SAHA, compared with control medium cells (0) (*P < 0.05). The mean ?SEM of three cell culture replicates is shown.

    Mol Carcinog 2012 52, 459-74. Vorinostat (SAHA, MK0683) purchased from Selleck.

    SAHA induces the down-regulation of cFLIP expression and promotes TRAIL-mediated activation of a mitochondrial-operated apoptotic pathway. a BT-474 cells were treated as indicated in Fig. 1 and the cells were then harvested to analyse caspase-8, Bid, caspase-9, caspase-3 and PARP expression, using GAPDH as the protein loading control. b BT-474 cells were treated with SAHA for 8 h at the doses indicated and subsequently, the cells were harvested and the apoptosis-related proteins were analysed in western blots as described in the "Materials and Methods". The results shown are representative of at least three independent experiments

    Invest New Drugs 2012 30, 541-547. Vorinostat (SAHA, MK0683) purchased from Selleck.

  • Treatment with SAHA sensitizes breast cancer cells to TRAILinduced apoptosis. BT-474 and MDA-MB-231 cells were incubated for 8 h with SAHA at the doses indicated. After this time, TRAIL (500 ng/ml) was added to some of the cultures for an additional 15 h. Apoptosis was measured as the percentage of cells with subG1 DNA content as described in the "Materials and methods". The results show the mean and S.E.M. of three independent experiments

    Invest New Drugs 2012 30, 541-547. Vorinostat (SAHA, MK0683) purchased from Selleck.

    SAHA facilitates the Itch/AIP4-independent proteasomal degradation of cFLIP proteins in breast cancer cells. a BT-474 cells were treated with SAHA (5 μM) for 8 h in the presence or absence of the proteasome inhibitors MG132 or epoxomicin (at the doses indicated), and they were then harvested and the cFLIP content was analysed in western blots. b BT-474 cells were transfected with either the siRNA oligonucleotides targeting Itch/AIP4 or the non-targeting RNA oligonucleotide (scrambled) for 48 h as described in the "Materials and Methods". Subsequently, the cells were treated with SAHA (5 μM) for 8 h and then cFLIP and Itch/AIP4 expression was analysed in immunoblots

    Invest New Drugs 2012 30, 541-547. Vorinostat (SAHA, MK0683) purchased from Selleck.

  • cFLIP down-regulation following SAHA treatment is responsible for the sensitization of breast cancer cells to TRAIL. a BT-474 cells were transfected with either different siRNAs directed against the cFLIP isoforms or the non-targeting RNA oligonucleotide (scrambled) as described in the "Materials and Methods". After 24 h, the cells were treated with TRAIL (500 ng/ml) for a further 15 h and apoptosis was then measured as the percentage of cells with subG1 DNA content. The results show the mean and S.E.M. of three independent experiments. To verify protein knockdown, cells were harvested 24 h after transfection and the cFLIP levels were assessed in immunoblots. b. BT-474 cells overexpressing Cflipl (pBABE-FLIPL) or control cells (pBABE) were treated with SAHA for 8 h at the doses indicated. After this time, TRAIL (500 ng/ml) was added to some cultures for 15 h. Apoptosis was measured as the percentage of cells with subG1 DNA content and the results show the mean and range of two independent experiments. Western blots show the cFLIP levels after SAHA treatment in pBABE and pBABE-FLIPL cells.

    Invest New Drugs 2012 30, 541-547. Vorinostat (SAHA, MK0683) purchased from Selleck.

    Vorinostat inhibits the tumor growth. NOD ⁄ SCID-B2m-/-mice were injected s.c. with 1×106 MyLa2059 cells into both flanks. When the mice had developed established palpable tumors treatment was initiated (day 1). The mice received either vehicle (black line) or 60 mg ⁄ kg vorinostat (grey line) i.p. five days a week. In total, there were four mice in the group receiving vehicle and three mice in the group receiving vorinostat. The length and width of the tumors were measured continuously until the experiment was terminated on day 20 post treatment initiation. The tumor volume was calculated using the formula V = (a×b2)/2, where a defines the length (mm) and b the width (mm) of the tumor. The histogram shows the average tumor volume per flank ± SEM. * denotes a significant difference (P < 0.05) in the average tumor volume per flank between mice treated with vehicle and vorinostat at the given time-point both by using a one-tailed two samples test with Welch, scorrection and a Mann-Whitney U test.

     

     

    Exp Dermatol 2010 19, 1096-1102. Vorinostat (SAHA, MK0683) purchased from Selleck.

  • (a) Western blot of whole cell extracts demonstrates SAHA and NaB treatment result in increased levels of acetylated histone H3 compared to vehicle controls. (b) Light micrographs of HDACi/vehicle treated cultures illustrate the paucity of neurospheres in HDACi-treated cultures. (c) Quantitative analysis confirms SAHA and NaB inhibit the formation of neurospheres (diameter ≥ 50 μm) and increase the prevalence of small cell clusters (≥ 4 cell, diameter < 50 μm). (d) Flow cytometry using LIVE/DEAD cell stain confirms SAHA and NaB are minimally toxic compared to vehicle controls (n = 3). Scale bar = 100 μm.

    BMC Neurosci 2011 12, 50. Vorinostat (SAHA, MK0683) purchased from Selleck.

    (a) EdU flow cytometry of live cell-gated adult mouse NSCs demonstrates SAHA (**p < 0.01) and NaB (***p < 0.001) significantly inhibit DNA synthesis. (b) Analysis of DNA content by flow cytometry reveals significant accumulation of adult mouse NSCs in G1phase of the cell cycle following SAHA (*p < 0.05) and NaB (*p < 0.05) treatment. (c) Correspondingly the proportion of cells in G2/M phase is significantly reduced following SAHA (*p < 0.05) and NaB (*p < 0.05) treatment. (d) Fluorescence micrographs of HDACi/vehicle treated adult NSCs pulse-labeled with EdU for flow cytometry. Scale bar = 50 μm. Statistical comparisons performed using one-way ANOVA with post hoc Newman-Keuls multiple comparison tests.

    BMC Neurosci 2011 12, 50. Vorinostat (SAHA, MK0683) purchased from Selleck.

  • (a) Immunofluorescence labeling of NeuN, GFAP and Olig2 cell fate markers reveals reduced expression of GFAP (*p < 0.001) and Olig2 (*p < 0.05) in adult mouse NSCs treated with SAHA for 48 hours under proliferation culture conditions and then induced to differentiate for 14 days in culture (two-way ANOVA with Bonferroni post-tests). (b) Western blot of β-catenin protein in nuclear and cytoplasmic fractions of adult mouse NSCs treated with HDACi/vehicle control under proliferation culture conditions. Gapdh and lamin A/C blots are included as loading controls. (c) SAHA and NaB do not significantly alter nuclear/cytoplasmic levels of β-catenin in adult mouse NSCs. Histogram of β-catenin Western blot signal intensities normalized to loading controls (n = 4).

    BMC Neurosci 2011 12, 50. Vorinostat (SAHA, MK0683) purchased from Selleck.

    Morphological changes and histone H3 phosphorylation of HB cells treated with a combination of VX-680 and SAHA. HUH6 and HepT1 were incubated with VX-680 (6 μM) and SAHA (0.5 μM). Nuclei diameter (a) and cell diameter (b) were determined 72 h later by DAPI staining and microscopy. Data represent mean±SD of the diameters from 20 cells in each experiment. (* Two-way ANOVA, Bonferroni test, p \0.05). c Western blot analysis on HUH6 and HepT1 cells were carried out with an anti-phospho-Histone H3 (Ser 10) antibody (p-H3) 24 h after incubation with VX-680 (10 μM), SAHA (0.2 μM) or a combination of both. Controls were left untreated. Western blot analysis showed a decrease in p–H3 after treatment with VX-680 ( lane 2 ) relative to controls ( lane 1 ) and an increase when SAHA was added ( lane 3 ). For the combination of VX-680 and SAHA (lane 4 ) no p-H3 was detected.

    Pediatr Surg Int 2012 28, 579-89. Vorinostat (SAHA, MK0683) purchased from Selleck.

  • Vorinostat promotes C2C12 differentiation.In the image, the red is the myotube indicating differentiation ,the blue is the nuclei.

     

     

    Dr. Akihiko Yoshimura of Akihiko Yoshimura. Vorinostat (SAHA, MK0683) purchased from Selleck.

    Western blot analysis of Acetyl-H3 and H3. 0-20μM SAHA was added.

     

     

    Dr. Zhang of Tianjin Medical University. Vorinostat (SAHA, MK0683) purchased from Selleck.

製品安全説明書

HDAC阻害剤の選択性比較

生物活性

製品説明 Vorinostat (suberoylanilide hydroxamic acid, SAHA) is an HDAC inhibitor with IC50 of ~10 nM in a cell-free assay.
ターゲット
HDAC [1]
(Cell-free assay)
~10 nM
体外試験

Vorinostat inhibits the activities of HDAC1 and HDAC3 with IC50 of 10 nM and 20 nM, respectively. Vorinostat also results in a marked hyperacetylation of histone H4. [1] Vorinostat inhibits the growth of three prostate cancer cell lines LNCaP, PC-3 and TSU-Pr1 at micromolar concentrations (2.5-7.5 μM), and induces dose-dependent cell death in LNCaP cells. [2] Vorinostat treatment in MCF-7 cells inhibits cell proliferation at an IC50 of 0.75 μM resulting in the accumulation of cells in the G1 and G2-M phase of the cell cycle. Vorinostat also induces differentiation in the estrogen receptor-negative cell line SKBr-3 and the retinoblastoma-negative cell line MDA-468. [3] Vorinostat treatment at 1 μM for 8 hours or more is sufficient to irreversibly induce apoptosis of human multiple myeloma (MM) cells. The gene expression profiles of Vorinostat treated MM cells are not hallmarked by global transcriptional activation, but by coordinated transcriptional changes of specific functional groups of genes such as cytokine-induced proliferative/survival signaling cascades, oncogenes-tumor suppressor genes, regulators of apoptosis, DNA synthesis-repair and cell cycle, and proteasome-ubiquitin function. [4]
細胞データ
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
A20 M2nl[2tqdmG|ZTDBd5NigQ>? NGCyNYkyKGh? M3[1UmROW09? MnTMZY51cS2KRFHDNUBi[3Srdnn0fUB4cXSqIFnDOVAhd2ZiMD6xNVIh|ryP MVGxNVk3ODR6OR?=
Friend leukemic cell MlzMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml;rOVAh|ryP MWe3NkBp M4T1c2ROW09? M{W2O2lEPTB;MD65PUDPxE1? MmLsNVIyODl7MUO=
K562 M3vqXmtqdmG|ZTDBd5NigQ>? NUH6[ZY4PiCq M1Hib2ROW09? NVX6eG1IUW6qaXLpeIlwdiCxZjDoeY1idiCqaYP0c45mKGSnYXPleJlt[XOnIDjtbZh1fXKnIH;mJGhFSUNzIHHu[EBJTEGFMjmge4l1cCCLQ{WwJI9nKDBwMEGg{txO NVXwfXFEOTJ2MUmzPFA>
HT1080 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV65enVYPzJiaB?= M2P2bWROW09? MYHJR|UxRTJwNDFOwG0> NFGzPVAyOjJ5MEG3OS=>
H1299 MXjLbY5ie2ViQYPzZZk> NV3HclhOOjBibXnu NIjG[JBFVVOR MlLTTY5pcWKrdH;yfUBi[3Srdnn0fUBi\2GrboP0JGhFSUNiZX76fY1mKHerdHigTWM2OCCxZjCwMlE6PCEQvF2= NF\3fIYyPDV{MUSyNi=>
H1299 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWe3NkBp MVjEUXNQ NVP6N3hKUUN3ME23MlI1KM7:TR?= M1rFSlE1PTJzNEKy
HeLa NIW0SIhMcW6jc3WgRZN{[Xl? NIrKd4Y{OCCvaX6= NUDkfpNtUW6qaXLpeI9zgSClb37j[Y51emG2aX;uJIFo[Wmwc4SgbIl{fG:wZTDk[YFk\XS7bHHz[UB4cXSqIFnDOVAhd2ZiMD6yPEDPxE1? M{fh[|E2PjB|OUS5
LOX-IMVI NE\OW4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlPnOFghcA>? NH;YSpBKSzVyPUGuN{DPxE1? MX2xOVcyPTR5MB?=
NCI-H226 NHuz[WRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkXnOFghcA>? NIjsWWRKSzVyPUKuOkDPxE1? NXn0cYtkOTV5MUW0O|A>
RXF-631L MojYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnjROFghcA>? NXfLNXdTUUN3ME2yJO69VQ>? MXuxOVcyPTR5MB?=
SNB-78 M2XkeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3\pTVQ5KGh? NUHRb415UUN3ME2xOkDPxE1? Mn3SNVU4OTV2N{C=
St-4 Ml3tS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn3MOFghcA>? MkTBTWM2OD13LkKg{txO NVHUU5h{OTV5MUW0O|A>
ARP1 NHjQepNHfW6ldHnvckBCe3OjeR?= M{HvUVIh|ryP MXi2JIg> MnfhTY5lfWO2aX;uJI9nKFB{MWfBSlEh\2WwZTDlfJBz\XO|aX;u M{TzNlE1PzN2OEC2
CEM Mlm0T4lv[XOnIFHzd4F6 M1u1cVEhcA>? NIHr[ZRFVVOR M3fxXWlvcGmkaYTpc44hd2ZiSFTBR{B4cXSqIFnDOVAhd2ZiMD6zN{DPxE1? MmPYNVY1OjByNkS=
HCT15 NHnjfY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEDLfJQ1QCCq MV\HTVUxRTBwOEKg{txO NWPWUJZCOTZ5MkOyNlc>
NCI-H23 M2HOSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUm0PEBp NG\sOJBIUTVyPUCuPVIh|ryP NYrlSI83OTZ5MkOyNlc>
GM15850 NV3wSGt6U2mwYYPlJGF{e2G7 NEHUU4YzNjVizszN MkDJPVYhcA>? NHLBZpFFVVOR NUTHeIVJUW6qaXLpeIlwdiCxZjDISGFEKGG|c3Xzd4VlKGG|IHnuZ5Jm[XOnIHnuJIhqe3SxbnWgTFMhdHm|aX7lJFE1KGGlZYT5cIF1cW:wIH;mJGZZViCpZX7l M2rZZVE3QTJzM{[3
GM15850 M{TvPWtqdmG|ZTDBd5NigQ>? NVm5Too3Oi53IN88US=> NF32c5M6PiCq M2\lNWROW09? MojHTY5pcWKrdHnvckBw\iCKRFHDJIF{e2W|c3XkJIF{KGmwY4LlZZNmKGmwIHjpd5RwdmViSESgcJl{cW6nIEWgZYNmfHmuYYTpc44hd2ZiRmjOJIdmdmV? NFO3[3gyPjl{MUO2Oy=>
GM15850 MlvVT4lv[XOnIFHzd4F6 MX2yMlUh|ryP MWW5OkBp MliySG1UVw>? MnS2TY5pcWKrdHnvckBw\iCKRFHDJIF{e2W|c3XkJIF{KGmwY4LlZZNmKGmwIHjpd5RwdmViSESgcJl{cW6nIEGyJIFk\XS7bHH0bY9vKG:oIF\YUkBo\W6n MVixOlkzOTN4Nx?=
GM15850 M{S2cGtqdmG|ZTDBd5NigQ>? MUiyMlUh|ryP MV[5OkBp NID2dpZFVVOR NXi0WlJkUW6qaXLpeIlwdiCxZjDISGFEKGG|c3Xzd4VlKGG|IHnuZ5Jm[XOnIHnuJIhqe3SxbnWgTFMhdHm|aX7lJFkh[WOndInsZZRqd25ib3[gSnhPKGenbnW= MlW0NVY6OjF|Nke=
GM15850 Ml[xT4lv[XOnIFHzd4F6 NH;FRWgzNjVizszN NU[0UZRsQTZiaB?= Mkj2SG1UVw>? NIXwdGZKdmirYnn0bY9vKG:oIFjERWMh[XO|ZYPz[YQh[XNiaX7jdoVie2ViaX6gbIl{fG:wZTDIOEBtgXOrbnWgPEBi[2W2eXzheIlwdiCxZjDGXG4h\2WwZR?= MWOxOlkzOTN4Nx?=
GM15850 MlfPT4lv[XOnIFHzd4F6 M2S4S|IvPSEQvF2= M4\OOFk3KGh? NHv6cmtFVVOR M4PTOmlvcGmkaYTpc44hd2ZiSFTBR{Bie3Onc4Pl[EBieyCrbnPy[YF{\SCrbjDobZN1d26nIFi0JIx6e2mwZTCxOkBi[2W2eXzheIlwdiCxZjDGXG4h\2WwZR?= MYGxOlkzOTN4Nx?=
U937 MX7GeY5kfGmxbjDBd5NigQ>? NFLmUI82KM7:TR?= NXrYTpFWOjRiaB?= MWfEUXNQ Mn65R4VtdCCleXPs[UBienKnc4SgZpkh[WOldX31cIF1cW:wIHH0JHMwTzJxTTDwbIF{\Q>? M1G4V|E4ODB2N{G4
H661 NF\nboJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4PySVQ5KGh? NXf5bnpPUUN3ME2xJO69VQ>? Ml[3NVcyPTdyMEm=
U937 NFnoNmVHfW6ldHnvckBCe3OjeR?= MmDZOUDPxE1? MlfNNlQhcA>? NVnZUVN{TE2VTx?= NFz6UGtKdmO{ZXHz[UBqdiCqaYP0c45mKEh|IHHj[ZR6dGG2aX;u M1X0[|E4PDR5N{Ww
U937 NGrh[4JHfW6ldHnvckBCe3OjeR?= NFToUHIyKM7:TR?= NEDn[lEzPCCq M4\lSmROW09? M17mS2Vn\mWldDDvckBidHCqYTD0eYJ2dGmwIHHj[ZR6dGG2aX;u MoHUNVc1PDd5NUC=
RAW264.7 MmrJSpVv[3Srb36gRZN{[Xl? MVOxNEDPxE1? MlLsNlRp NV7FTmd3f2G2ZYK= NXXsc4JqUW6qaXLpeIlwdiCxZjDMVHMue3SrbYXsZZRm\CCWTl\hcJBp[SCycn;keYN1cW:wIIfpeIghUUN3MDDv[kAxNjd4IN88US=> NUG3ToIzOTd2N{e1NVg>
RAW264.7 M2rEZWZ2dmO2aX;uJGF{e2G7 NGLDfXcyOCEQvF2= NYS0XZhFOjSq NWPyc2JEf2G2ZYK= Mm\zTY5pcWKrdHnvckBw\iCOUGOtd5RqdXWuYYTl[EBPVyCycn;keYN1cW:wIIfpeIghUUN3MDDv[kAyNjh6IN88US=> MnfjNVc1Pzd3MUi=
SC9 NV\NVZFTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXvpcWtKPDhiaB?= M2fiTmlEPTB;MD62NFYh|ryP M3;OWFE4PTB5MkG5
ST14A NGfy[Y1HfW6ldHnvckBCe3OjeR?= NVLyN3NGPSCwTR?= MkXvO|IhcA>? M37CR2lv[3KnYYPlJIlvKFKHU2SvUnJUTiCvUl7BJIV5eHKnc4Ppc44> NV;NWI5kOTd3NkW5PVM>
ST14A MmLQSpVv[3Srb36gRZN{[Xl? MUK1JI5O NVX5e2I1PzJiaB?= NVPpbnVKUW6lcnXhd4UhcW5iRULGNUBuWk6DIHX4dJJme3Orb36= MWCxO|U3PTl7Mx?=
PANC1 MojNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUXMSYFHOSEQvF2= Mn;iTWM2OD1yLkS1JO69VQ>? MY[xO|U5QDd2NB?=
PANC1 NYTDbVh4TnWwY4Tpc44hSXO|YYm= NGmzZ2oyKM7:TR?= NHvzdlIzPCCq MljITY5kemWjc3WgbY4heDJzV1HGNU9EUVBzIHflcoUh\XiycnXzd4lwdg>? MYmxO|U5QDd2NB?=
PANC1 NF\oZVRHfW6ldHnvckBCe3OjeR?= NVLLfVZvOSEQvF2= NVT5eZc5OjRiaB?= NVS0U4p3UW6lcnXhd4UhcW5icEK3b4lxOSCpZX7lJIV5eHKnc4Ppc44> MYmxO|U5QDd2NB?=
PT45 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkLTTWM2OD12IN88US=> M1T0UVE4PTh6N{S0
ACHN MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NILMelYzOSCq NEXMc2FIUTVyPUCuOlUh|ryP MX2xO|Y3OjZyNh?=
PC3 NGrlNHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUHVb5JHOjFiaB?= NVGyOYN1T0l3ME2wMlcyKM7:TR?= MmX1NVc3PjJ4ME[=
A431 MXrDfZRwfG:6aXOgRZN{[Xl? NEHmWo04OiCq M1zGNWlEPTB;ND6yJO69VQ>? NXu1[XZrOTd4OUG3OlM>
Cal27 M4DzcmN6fG:2b4jpZ{BCe3OjeR?= M2\X[FczKGh? NE\wWHJKSzVyPUOuNkDPxE1? MlXENVc3QTF5NkO=
CCRF-CEM NFnsZpVEgXSxdH;4bYMhSXO|YYm= M{jZRlczKGh? Ml7RTWM2OD1yLkig{txO NVvKPY14OTd4OUG3OlM>
EOL1 NF;XdpdEgXSxdH;4bYMhSXO|YYm= MkLtO|IhcA>? NYnDdW03UUN3ME2xJO69VQ>? M37jc|E4PjlzN{[z
Hec-1-A MmnMR5l1d3SxeHnjJGF{e2G7 MkfRO|IhcA>? NVi2TmUzUUN3ME2xJO69VQ>? NVfTeWZyOTd4OUG3OlM>
HeLa NYrF[4J3U2mwYYPlJGF{e2G7 M1eydVExKM7:TR?= NXzTeJRiOzBibXnu NXTxcYlbTE2VTx?= M{nGeGlvcGmkaYTpc44hd2ZicnXjc41jcW6jboSgTGRCSzFid3n0bEBKSzVyIH;mJFAvODJizszN M3vEc|E4PjlzN{[z
RKOp21 NEW5U3lEgXSxdH;4bYMhSXO|YYm= M2fqSlczKGh? NGjRV|VKSzVyPUGuO|Yh|ryP NEHwdZcyPzZ7MUe2Ny=>
Saos2 MV;DfZRwfG:6aXOgRZN{[Xl? MmX0O|IhcA>? MYLJR|UxRTJwMzFOwG0> MVqxO|Y6OTd4Mx?=
SK-OV-3 NEfFTGlEgXSxdH;4bYMhSXO|YYm= M3f2c|czKGh? NVnBNGlYUUN3ME2yMlIh|ryP M3nZXVE4PjlzN{[z
U87MG MYLDfZRwfG:6aXOgRZN{[Xl? Mn\SO|IhcA>? M{XSVGlEPTB;MUGg{txO MXOxO|Y6OTd4Mx?=
NUGC3 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGXvWpg2KM7:TR?= NHrWeIIzPCCq MnHaS2k2OD1{Lke5JO69VQ>? NFryfIMyPzlyNEi0Ny=>
CCD1059SK NXzNSIZpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHzjb2tKSzVyPUSzMlUh|ryP NULJSWxpOTh{NEe1OVQ>
HepG2 NIfRdVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml;2TWM2OD1yLkCwNFYh|ryP NH7ub28yQDJ2N{W1OC=>
HT1080 M4KzZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mnu1TWM2OD1yLkCwNlQh|ryP MnvpNVgzPDd3NUS=
SKBR3 NF;jXYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIHvUnZKSzVyPUCuPEDPxE1? M{TZSFE5OjR5NUW0
SNB78 NEmwSGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MY\FR|UxRTF4IN88US=> MYexPFI1PzV3NB?=
SQ20B MmL6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV\XOVZMUUN3ME2zJO69VQ>? Mn;iNVgzPDd3NUS=
St4 M4XkWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYnFR|UxRTVwMjFOwG0> M{jITlE5OjR5NUW0
MCF7 NFLVb3lHfW6ldHnvckBCe3OjeR?= NXfwb5BOOTBizszN MV64JIg> NH\mbpRFVVOR M4XpSmlv\HWldHnvckBw\iC2dXL1cIlvKGi7cHXyZYNmfHmuYYTpc44> NULjSWI4OTh{NkmyNlY>
HEK293 MkP2T4lv[XOnIFHzd4F6 NXvBRmx1OSCq Ml;nSG1UVw>? NGGwdYNKdmirYnn0bY9vKG:oIFjERWMyKHerdHigTWM2OCCxZjCwMlA{KM7:TR?= MmXtNVg{ODh3NkO=
HEK293 NUfDdJJmU2mwYYPlJGF{e2G7 MWCxJIg> MVvEUXNQ Mln5TY5pcWKrdHnvckBw\iCKRFHDN{B4cXSqIFnDOVAhd2ZiMD6wOVch|ryP MljmNVg{ODh3NkO=
G401 NGizNYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3XVNlczKGh? M{LXSGROW09? MXvJR|UxRTFizszN M1faRVE5OzdyM{ez
HeLa M4\yPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlO1O|IhcA>? MXnEUXNQ NGm0fmRKSzVyPUCuOFYh|ryP M{fsclE5OzdyM{ez
Human renal epithelial cell MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVfzNmhyPzJiaB?= MU\EUXNQ MWjJR|UxRTF2IN88US=> M33zW|E5OzdyM{ez
U937 NELXTJNHfW6ldHnvckBCe3OjeR?= MU[1JO69VQ>? Ml23NlQhcA>? NIHKTI5KdmS3Y4Tpc44hd2ZiaHnzeI9v\SCKNDDofZBmemGlZYT5cIF1cW:w M1qzeVE5OzhzMkO4
U937 MVLGeY5kfGmxbjDBd5NigQ>? NI\KT242KM7:TR?= NV[5fFUyOjRiaB?= M1X4dWlv\HWldHnvckBw\iCjbIDoZUB1fWK3bHnuJIh6eGW{YXPleJlt[XSrb36= MYixPFM5OTJ|OB?=
U937 NVXwXnVYTnWwY4Tpc44hSXO|YYm= NV\KUFE2PSEQvF2= M3f3flI1KGh? M37PNGlv\HWldHnvckBw\iCyMkGg[ZhxemW|c3nvci=> MkPYNVg{QDF{M{i=
U937 M3n1cWZ2dmO2aX;uJGF{e2G7 NG\4eXA2KM7:TR?= M2W4[|I1KGh? NI\OdpBKdmS3Y4Tpc44hd2ZiYYDvdJRwe2m| M2XEbVE5OzhzMkO4
U937 MX;GeY5kfGmxbjDBd5NigQ>? M3nwUFUh|ryP MYCyOEBp Mn7HTY5lfWO2aX;uJI9nKGe{YX71cI9kgXSrYzDkbYZn\XKnboTpZZRqd25? MlOzNVg{QDF{M{i=
U937 MXLLbY5ie2ViQYPzZZk> MX21JO69VQ>? Ml71NlQhcA>? NFvm[pZKdmirYnn0bY9vKG:oIHj1cYFvKEiGQVOx NITBVVkyQDN6MUKzPC=>
U937 NFHqUlJMcW6jc3WgRZN{[Xl? M1S3fFUh|ryP MUKyOEBp MkPZTY5pcWKrdHnvckBw\iCqdX3hckBJTEGFNB?= M37NNVE5OzhzMkO4
HEK-TE M2PzfWZ2dmO2aX;uJGF{e2G7 NVrqSZoyPSEQvF2= NF;UWnM3cA>? M1znd2ROW09? NVPQT2lvUW6lcnXhd4UhcW5iaHnzeI9v\SCKMzDhZ4V1gWyjdHnvci=> NFrqfWwyQDR|NEG0OC=>
HPDE6c7 NXPqfYNvS3m2b4TvfIlkKEG|c3H5 MnnnOVAh|ryP Mn7RO|IhcA>? NWezT5ZyTE2VTx?= M3jkWGlEPTB;MT6zJO69VQ>? M1nRelE5PDl2NE[z
Human microvascular epithelial cell M1TmXmN6fG:2b4jpZ{BCe3OjeR?= M1;JOFUxKM7:TR?= M2HB[lczKGh? NETkbYhFVVOR NFjCUGxKSzVyPUGuN{DPxE1? NV20NWl5OTh2OUS0OlM>
Hup T3 NFO3TGZEgXSxdH;4bYMhSXO|YYm= MmjEOVAh|ryP M2rLelczcA>? NVX1epFQTE2VTx?= NHy5UWNKSzVyPUCuPEDPxE1? M4fmTVE5PDl2NE[z
Mia Paca2 MU\DfZRwfG:6aXOgRZN{[Xl? NH;mc3M2OCEQvF2= NXK2XYZwPzKq Mm\hSG1UVw>? M4TJd2lEPTB;MT6xJO69VQ>? NGnzS5UyQDR7NES2Ny=>
Panc 04.03 NEfmXFBEgXSxdH;4bYMhSXO|YYm= Ml;4OVAh|ryP M1z5[FczcA>? M4OxcmROW09? NWfvS28yUUN3ME2xMlIh|ryP NIXhS2wyQDR7NES2Ny=>
SU 86.86 MVjDfZRwfG:6aXOgRZN{[Xl? MXW1NEDPxE1? NETO[HQ4Omh? M{fCR2ROW09? M17YNWlEPTB;MT6zJO69VQ>? MkOxNVg1QTR2NkO=
HEK293 NGTtdmRMcW6jc3WgRZN{[Xl? NFzJN3Y{KGh? NV7YRmZHUW6qaXLpeIlwdiCxZjDy[YNwdWKrbnHueEBJTEGFNjDlfJBz\XO|aX;uJJdqfGhiSVO1NEBw\iByLkCxPUDPxE1? M13MXlE5PTV6Nk[5
HeLa MnvjT4lv[XOnIFHzd4F6 NYPiXpk1OiCq NFLEeJZKdmirYnn0bY9vKG:oIH71Z4xm[XJiSFTBR{B4cXSqIFnDOVAhd2ZiMD6wPFMh|ryP M4DmWVE5PTV6Nk[5
RAW264.7 NVy2TJc6TnWwY4Tpc44hSXO|YYm= M1;jU|Ih|ryP NXzFfFQxOy53IHi= Ml7pSG1UVw>? NI[zbGRCdnSrbXHsZZJq[WxiYXP0bZZqfHliYXfhbY5{fCCSbHHzcY9lcXWvIH\hcINqeGG{dX2gbY5n\WO2ZXSge4l1cCCLQ{WwJI9nKDBwMUGg{txO NX3qWZdbOTh4NES5Olk>
NB4 MWm0PIg> NXPSeWxYTE2VTx?= MU\JR|UxRTBwNjFOwG0> NEjjR5MyQDd{M{O0PS=>
HEK293 MlTOSpVv[3Srb36gRZN{[Xl? M37RfFExKM7:TR?= M1HQXFI1KGh? M{XlSGROW09? NFjqZmFC[3SrdnH0bY9vKG:oIH3veZNmKFewdEPhJJNq\26jbHnu[{BmgHC{ZYPz[YQ> MV6xPVAzOjZ5NR?=
HCT116 NH;5c5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFr6fZI4Omh? Mn7ySG1UVw>? MWnJR|UxRTBwM{Gg{txO M{D5PFE6ODh2Mkm0
HeLa NYXjWGZUU2mwYYPlJGF{e2G7 NViweVR[OiEQvF2= NVXYS4c4OzBibXnu MmPwSG1UVw>? M1fFcGlvcGmkaYTpc44hd2ZiSFTBR|IhcW5iaIXtZY4hUGWOYTDj[YxteyC5aYToJGlEPTBib3[gNE4yKM7:TR?= M{DtWlE6ODh2Mkm0
IGROV1 NGHTcWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGXRfFg4OiCq Mn3HSG1UVw>? NFfBdVdKSzVyPUKuNkDPxE1? MoDwNVkxQDR{OUS=
IGROV1 M4D3SWtqdmG|ZTDBd5NigQ>? Mn;FOUDPxE1? Mn76NlQhcA>? MXnEUXNQ M3nOU2lvcGmkaYTpc44hd2ZiSFTBR{Bie3Onc4Pl[EBieyCyNUOgZYNmfHmuYYTpc44> NWrTR4JnOTlyOESyPVQ>
IGROV1 MXvLbY5ie2ViQYPzZZk> NVjHcmo{OTBizszN M4nh[lQhcA>? NF32dVlFVVOR MVHJcohq[mm2aX;uJI9nKEiGQVOgZZN{\XO|ZXSgZZMhcGm|dH;u[U1JPCCjY3X0fYxifGmxbh?= NIrBeHoyQTB6NEK5OC=>
IGROV1 MlPzT4lv[XOnIFHzd4F6 MXKxNEDPxE1? M{PHe|QhcA>? NYLUdFhGTE2VTx?= Mn6xTY5pcWKrdHnvckBw\iCKRFHDOkBie3Onc4Pl[EBieyCjbIDoZU11fWK3bHnuJIFk\XS7bHH0bY9v NYm4dY5TOTlyOESyPVQ>
T24 MlHYT4lv[XOnIFHzd4F6 NFTFeXQ{KGh? M4jnUWlv\HWldHnvckBw\iCqaYP0c45mKEh|IHHj[ZR6dGG2aX;uJJdqfGhiRVO1NEBw\iByLkGyJO69VQ>? NXnjS2JqOTlyOESzPVU>
T24 M2rmZWtqdmG|ZTDBd5NigQ>? Ml3aN{Bp MoHYTY5lfWO2aX;uJI9nKGGucHjhJJR2[nWuaX6gZYNmfHmuYYTpc44hf2m2aDDFR|UxKG:oIECuNlUh|ryP MWqxPVA5PDN7NR?=
HeLa MoLhT4lv[XOnIFHzd4F6 MnHQNVUhdWmw NHO1cm9FVVOR M{XOdGlvcGmkaYTpc44hd2ZiSFTBR|Yh\nKxbTDueYNt\WG{IHX4eJJi[3Rid3n0bEBKSzVyIH;mJFAvODh3NTFOwG0> NWftRo06OTlyOUO4PFQ>
HeLa MWHLbY5ie2ViQYPzZZk> Mn;MNVUhdWmw MnziSG1UVw>? NYjN[3VPUW6qaXLpeIlwdiCxZjDISGFEQCCocn;tJI52[2ynYYKg[Zh1emGldDD3bZRpKEmFNUCgc4YhOS56NjFOwG0> MmD2NVkxQTN6OES=
NCI-H69 NFLG[JZEgXSxdH;4bYMhSXO|YYm= NGXMWnU4OiCq M2XBOWROW09? MYrJR|UxRTJwME[g{txO NWPHPVhCOTlyOUO4PFQ>
SKMES1 NWKwU2JuS3m2b4TvfIlkKEG|c3H5 NWn6PJJvPzJiaB?= NFnjXXBFVVOR M2izOGlEPTB;Mj60NkDPxE1? MWqxPVA6Ozh6NB?=
S2 Ml\1T4lv[XOnIFHzd4F6 M2HhW|AvOS1zMDFOwG0> M2XpdFEhcA>? NEDEfm1KdmirYnn0bY9vKG:oIGDsZZNud2SrdX2g[oFt[2myYYL1cUBJTEGFMTDlfJBz\XO|ZXSge4l1cCCLQ{WwJI9nKDBwMEW5JO69VQ>? M2DqOlE6OzF5NEWw
SHSY5Y M1m1RWtqdmG|ZTDBd5NigQ>? MX2xNEDPxE1? NEG4TGw1QCCq NGnKWXFFVVOR NX7L[FlbUW6qaXLpeIlwdiCxZjDISGFEKHerdHigTWM2OCCxZjCwMlUh|ryP MYexPVM1PDF5NR?=
SHSY5Y NWHMcINRS3m2b4TvfIlkKEG|c3H5 NVnHS5lrOTBizszN MlzNOFghcA>? MXrEUXNQ NIPncnBKSzVyPUKg{txO MkTJNVk{PDRzN{W=
DMS114 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MW[0PEBp NXf1[HhqT0l3ME2yMlkh|ryP MUixPVQyQTJyNR?=
HBC5 M3f4[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIPGOIU1QCCq MmrGS2k2OD1zNzFOwG0> NYHyd2dHOTl2MUmyNFU>
SNB78 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoLLOFghcA>? MWPHTVUxRTF4IN88US=> NWH0XYd6OTl2MUmyNFU>
HeLa Mn\PS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWe3NkBp MnHmSG1UVw>? MWPJR|UxRTBwNE[g{txO MV2xPVQ1OTh2Nh?=
BHK MXnLbY5ie2ViQYPzZZk> NW\2[WN4PSEQvF2= NYrjcXp5OjRiaB?= NVmxSnRGTE2VTx?= NY\kO2pKUW6qaXLpeIlwdiCxZjDISGFEPyCneIDy[ZN{\WRiYYPz[ZN{\WRiYYOgbY5kemWjc3WgbY4heGyjc33hJI1mdWK{YX7lJGZl\Wy2YUWwPEBETlSUIIDyc5RmcW5? M2TxPFE6QTZ4N{i5
CFBE41o- MXjLbY5ie2ViQYPzZZk> M3fzelUh|ryP NXzrWJNtQCCq MVrEUXNQ NVnlTYg2UW6qaXLpeIlwdiCxZjDISGFEKGG|c3Xzd4VlKGG|IHj5dIVz[WOndInsZZRqd25ib3[gbIl{fG:wZTDINy=> NWW0UGhxOTl7Nk[3PFk>
CFBE41o- M{P2[mtqdmG|ZTDBd5NigQ>? MVq1JO69VQ>? M2CySFQhcA>? M4XUfWROW09? MWjJcohq[mm2aX;uJI9nKEiGQVOgZZN{\XO|ZXSgZZMhcW6lcnXhd4UhcW5ibYX0ZY51KE[mZXz0ZVUxQCCFRmTSJJBzd3SnaX6gcIV3\Wx? M2q4NFE6QTZ4N{i5
CFBE41o- Mlu1T4lv[XOnIFHzd4F6 NYjyVm1[OSEQvF2= M1THRVEhcA>? MkS3SG1UVw>? MVTJcohq[mm2aX;uJI9nKEiGQVOgZZN{\XO|ZXSgZZMhcW6lcnXhd4UhcW5iQ1\UVkBxem:2ZXnuJIxmfmWu M{fGPVE6QTZ4N{i5
Primary bronchial epithelial cell MkKxT4lv[XOnIFHzd4F6 M1nYc|Eh|ryP NETqdZMzPCCq Ml7GSG1UVw>? NXPCO4VMUW6qaXLpeIlwdiCxZjDISGFEPyCjc4Pld5Nm\CCjczDpcoR2[3Srb36gc4YhdXW2YX70JGZl\Wy2YUWwPEBETlSUIIDyc5RmcW5iYYDpZ4FtKHO3cn\hZ4UhdG:lYXzpfoF1cW:w NH3RbmkyQTl4Nke4PS=>
CFBE41o- MYfLbY5ie2ViQYPzZZk> MYOxJO69VQ>? MXe1JIRigXN? M2qwZmROW09? MV;Jcohq[mm2aX;uJI9nKEiGQVO3JIF{e2W|c3XkJIF{KGmwY4LlZZNmKGmwIIP0ZYJqdGm8YYTpc44hd2ZiRnTlcJRiPTB6IFPGWHIheHKxdHXpci=> MX[xPVk3Pjd6OR?=
CFBE41o- NILEU4dMcW6jc3WgRZN{[Xl? MmXHNUDPxE1? NEXXRpEzPCCq MlPaSG1UVw>? Mlz0TY5pcWKrdHnvckBw\iCKRFHDO{Bie3Onc4Pl[EBieyCrbnPy[YF{\SCrbjDG[IVtfGF3MEigR2ZVWiCycn;0[YlvKHS{YX\mbYNscW6p Mn\2NVk6PjZ5OEm=
CFBE41o- M2rmUWtqdmG|ZTDBd5NigQ>? NI\5dmo2KM7:TR?= NF:xfXMzPCCq NFHEVYlFVVOR Ml;qTY5pcWKrdHnvckBw\iCKRFHDO{Bie3Onc4Pl[EBieyCrbnPy[YF{\SCrbjDyZZRmKG:oIH3heJVz[XSrb36gc4YhS0[WUjDwdo91\WmwIITvJIl1eyCpbInjc4Zwem1? NEnwVFkyQTl4Nke4PS=>
CFBE41o- NUjncmJIU2mwYYPlJGF{e2G7 NITR[Ys2KM7:TR?= NVf0NFZ3OjRiaB?= Mn;BSG1UVw>? NHX2SpRKdmirYnn0bY9vKG:oIFjERWM4KGG|c3Xzd4VlKGG|IHnuZ5Jm[XOnIHnuJJN1[WKrbHn0fUBw\iCIZHXseIE2ODhiQ1\UVkBxem:2ZXnu MlPMNVk6PjZ5OEm=
CFBE41o- NITHcY5McW6jc3WgRZN{[Xl? Mnv4OUDPxE1? NHzXbXkzPCCq MmmzSG1UVw>? MlntTY5pcWKrdHnvckBw\iCKRFHDO{Bie3Onc4Pl[EBieyClb4Ly[YN1cW:wIH;mJI12fGGwdDDG[IVtfGF3MEigR2ZVWiC2cnHm[olkc2mwZzD0c{Bk\WyuIIP1doZi[2ViYYOg[4x6[2:ob4Lt M{THS|E6QTZ4N{i5
Primary bronchial epithelial cell NVviTHNXU2mwYYPlJGF{e2G7 MkXKOUDPxE1? NVHoZW1yOjRiaB?= NWnpd5NWTE2VTx?= NYTZdnA5UW6qaXLpeIlwdiCxZjDISGFEKGG|c3Xzd4VlKGG|IHnu[JVkfGmxbjDv[kBufXSjboSgSoRmdHSjNUC4JGNHXFJicILveIVqdiCjcHnjZYwhe3W{ZnHj[UBtd2OjbHn6ZZRqd25? NX36XnBqOTl7Nk[3PFk>
Primary bronchial epithelial cell NFe1bHZMcW6jc3WgRZN{[Xl? MmH3NUDPxE1? Mn33PVYhcA>? NUfpRVVvTE2VTx?= NX\NNW1wUW6qaXLpeIlwdiCxZjDISGFEPyCjc4Pld5Nm\CCjczDpcoNz\WG|ZTDpckB{cG:{dDDjbZJkfWm2IHP1dpJmdnS| M2\QUlE6QTZ4N{i5
BxPC3 M320SGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3HvfVczKGh? NX34WlZNUUN3ME2yMlch|ryP NGnueHgzODF2M{e3PC=>
CAL27 NIW4O5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHTuU|I4OiCq NWj5Z5l{UUN3ME2zMlczKM7:TR?= MX[yNFE1Ozd5OB?=
Capan1 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3rJdVczKGh? NG\UemRKSzVyPUeuN{DPxE1? MlHsNlAyPDN5N{i=
HCC827 MlLxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHznPJk4OiCq MlzBTWM2OD1zLkig{txO MkLvNlAyPDN5N{i=
LNCAP M{e4UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2PSZlczKGh? NX3zflN3UUN3ME2wMlU5KM7:TR?= MVSyNFE1Ozd5OB?=
NCI-H2122 Ml;qS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEjRWGs4OiCq Ml7YTWM2OD15LkWg{txO MnrhNlAyPDN5N{i=
NCI-H358 M4jNOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnLBO|IhcA>? NGLTTIxKSzVyPUKuOUDPxE1? MYiyNFE1Ozd5OB?=
SCC15 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4jaclczKGh? MljqTWM2OD1{LkS5JO69VQ>? MmjKNlAyPDN5N{i=
SCC25 MnLjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGflWI04OiCq NFnYUmVKSzVyPUGuPVMh|ryP NH:1OGQzODF2M{e3PC=>
SKHEP1 NYn4bnlzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWq3NkBp Mn[2TWM2OD1|LkS2JO69VQ>? NGXGUJYzODF2M{e3PC=>
BJ NH6wTG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnThNVAxKM7:TR?= MYG0PEBp Mn;1SG1UVw>? NVriXXBWT3Kxd4ToJIlvcGmkaYTpc44h[XRiMD6wOUB1dyBzMECgeW0> MlWzNlAyPDN6NEC=
MUF M1TXRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmnwNVAxKM7:TR?= NXXid2ROPDhiaB?= NUnVUYp2TE2VTx?= MYTHdo94fGhiaX7obYJqfGmxbjDheEAxNjB3IITvJFExOCC3TR?= MYSyNFE1Ozh2MB?=
Caco-2 Mo[2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF:zcZUyODBizszN MXi0PIg> MVvEUXNQ M2foU2lEPTB;OD6xJO69VQ>? NHTHdZgzODF2M{i0NC=>
Caco-2 MkLaT4lv[XOnIFHzd4F6 M2GxVFUh|ryP MW[0JIg> M3O3OmROW09? M1njUmlv\HWldHnvckBw\iCKRFHDMY1m\GmjdHXkJIhqe3SxbnWgZYNmfHmuYYTpc44hUUN3MDDv[kAxNjB|NzFOwG0> NFjYT4kzODF2M{i0NC=>
Caco-2 Mn7NT4lv[XOnIFHzd4F6 M1zGfVAvOzF4IH7NJJRwKDNzLk[g{txO MUS0JIg> M2TUcmROW09? NVjsRVUxTXhidnn2c{BqdmirYnn0bY9vKG:oIHj1cYFvKEiGQVOxJJdqfGhiSVO1NEBw\iByLkGxPUDPxE1? MnryNlAyPDN6NEC=
Caco-2 NEXDfVFMcW6jc3WgRZN{[Xl? M2fWR|AvOzF4IH7NJJRwKDNzLk[g{txO NXrHfFM6PCCq MV3EUXNQ M2LSSWV5KH[rdn:gbY5pcWKrdHnvckBw\iCqdX3hckBJTEGFMzD3bZRpKEmFNUCgc4YhOC5zNEeg{txO MU[yNFE1Ozh2MB?=
Caco-2 M1fJXGtqdmG|ZTDBd5NigQ>? M3jlV|YvOzJibl2geI8hPjN{IN88US=> MYS0JIg> NETxSmJFVVOR Mnq1SZghfmm4bzDpcohq[mm2aX;uJI9nKGi3bXHuJGhFSUN3IIfpeIghUUN3MDDv[kAyOi54IN88US=> NF\YdG0zODF2M{i0NC=>
Caco-2 M3vXWWtqdmG|ZTDBd5NigQ>? MmfGOk4{OiCwTTD0c{A3OzJizszN NVeyWIp5PCCq MlfCSG1UVw>? NWXTW|hvTXhidnn2c{BqdmirYnn0bY9vKG:oIHj1cYFvKEiGQVO3JJdqfGhiSVO1NEBw\iB2MTFOwG0> Mo[4NlAyPDN6NEC=
Caco-2 NH7PZYFMcW6jc3WgRZN{[Xl? MkO1NE4{OTZibl2geI8hOzFwNjFOwG0> NHnZfI01KGh? NHG0bY9FVVOR NHG0PFBGgCC4aY\vJIlvcGmkaYTpc44hd2ZiaIXtZY4hUESDQ{[= NIfh[pMzODF2M{i0NC=>
HepG2 M{j0ZmtqdmG|ZTDBd5NigQ>? Ml\hOUDPxE1? NGPsXYU3cA>? M{T5OWROW09? NFvWUGtKdmS3Y4Tpc44hd2ZiSFTBR{1u\WSrYYTl[EBpcXO2b37lJIFk\XS7bHH0bY9v NYDCWo9uOjBzNEO4OFA>
HepG2 NX25eVNXU2mwYYPlJGF{e2G7 NHvQbIM2KM7:TR?= NHjHe403cA>? NUSw[IVKTE2VTx?= MmewTY5lfWO2aX;uJI9nKEiGQVOtcYVlcWG2ZXSgbIl{fG:wZTDofZBmemGlZYT5cIF1cW:w NULHNpNnOjBzNEO4OFA>
HepG2 MmL1T4lv[XOnIFHzd4F6 NIjHS2s2KM7:TR?= NGnRVpQ3cA>? M332VmROW09? MWLJcoR2[3Srb36gc4YhUESDQz3t[YRq[XSnZDDhcJBp[S22dXL1cIlvKGGlZYT5cIF1cW:w MnXZNlAyPDN6NEC=
HepG2 NILlT3ZMcW6jc3WgRZN{[Xl? NILMTIk2KM7:TR?= MmTzOog> MoK0SG1UVw>? NGnTNZhKdmS3Y4Tpc44hd2ZiSFTBR{1u\WSrYYTl[EBJOy:KNDDobZN1d26nIHHj[ZR6dGG2aX;u MVKyNFE1Ozh2MB?=
COLO205 NYLrUVlQU2mwYYPlJGF{e2G7 MVexNEDPxE1? M3\3Z|I1KGh? NX31NZdOTE2VTx?= MWXJcohq[mm2aX;uJI9nKEiGQVOxJIF{e2W|c3XkJIF{KGmwZIXjeIlwdiCxZjDobZN1d26nIFizJIFk\XS7bHH0bY9vKHerdHigTWM2OCCxZjCyMlIh|ryP MlvvNlA1PTF|N{i=
SCC4 MXLLbY5ie2ViQYPzZZk> M3\KUFEh|ryP M4rTNFI1cA>? MULJcohq[mm2aX;uJI9nKEiGQVOgZZN{\XO|ZXSgZZMhcW6lcnXhd4UhcW5idIXieYxqdiCjY3X0fYxifGmxbh?= Mn2zNlA1PTJ{MkW=
SCC4 MljnT4lv[XOnIFHzd4F6 MWixJO69VQ>? M{\DVFI1cA>? MYTJcohq[mm2aX;uJI9nKEiGQVOgZZN{\XO|ZXSgZZMhcW6lcnXhd4UhcW5iaHnzeI9v\SCjY3X0fYxifGmxbh?= M4nmRlIxPDV{MkK1
SCC4 MY\GeY5kfGmxbjDBd5NigQ>? NE\nSYsyKM7:TR?= M4rxdFUhdWmw MnLrRYdwdmm|dDDhZ5Rqfmm2eTDheEBXTFJiYYPz[ZN{\WRiYYOgbY5lfWO2aX;uJI9nKEO\UEK0JIdmdmViZYjwdoV{e2mxbh?= M3TOblIxPDV{MkK1
NB4 M3vwNWZ2dmO2aX;uJGF{e2G7 NVXsV|J5PSEQvF2= M2fBfFI1KGh? NHTPO3NFVVOR MWfD[YxtKGO7Y3zlJIFzemW|dDDhd5Nme3OnZDDhd{BqdmO{ZXHz[UBqdiCjY3P1cZVt[XSrb36gZZQheHKnLVexJJBp[XOn NVSzdpBsOjB2OUG0OFA>
NB4 M{Kz[2tqdmG|ZTDBd5NigQ>? NU\MXGlnPSEQvF2= M{XlWVI1KGh? Mo\hSG1UVw>? NF\DRoxKdmirYnn0bY9vKG:oIFjERWMh[XO|ZYPz[YQh[XNiaX7jdoVie2ViaX6gZYNmfHmuYYTlJJR2[nWuaX6gcIV3\Wx? M1[4[VIxPDlzNESw
NB4 NFPYRVVHfW6ldHnvckBCe3OjeR?= NF23Rnk2KM7:TR?= MoXXNlQhcA>? M33nZmROW09? NWXpdYRyUW6mdXP0bY9vKG:oIICyNXdCTjFxQ1nQNUBmgHC{ZYPzbY9v M4X4c|IxPDlzNESw
NB4 MWPLbY5ie2ViQYPzZZk> NVjhVYRmPSEQvF2= NF7weIUzPCCq NXTUdXZKTE2VTx?= NFrtV|lKdmirYnn0bY9vKG:oIFjERWMh[XO|ZYPz[YQh[XNiaX7jdoVie2ViaX6gbIl{fG:wZTDIN{Bi[2W2eXzheIlwdg>? MUeyNFQ6OTR2MB?=
NUGC3 M1LhOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4jWbWdKPTB;Mj65OEDPxE1? NYHPTnI4OjB6NUC5O|E>
A549 M4jx[GZ2dmO2aX;uJGF{e2G7 NEXmXWI2KM7:TR?= M3fCU|MhcA>? M2jzbmROW09? NF7W[VRKdmS3Y4Tpc44hd2ZiYYX0c5Bp[We7IHnuJIh2dWGwIFG1OFkh[2WubIOgZZN{\XO|ZXSgZZMhcW6lcnXhd4UhcW5iTFOzTWk> M{LzPVIxQDV3MkC4
HUT78 NEflXIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnTNO|IhcA>? M2\DSWROW09? MWLHTVUxRTBwMzFOwG0> NYjtUI5MOjB6OESyNFg>
U937 NETj[2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEf3ZWo4OiCq MoG3SG1UVw>? M{XjT2dKPTB;MD6zPUDPxE1? NXXXcYxqOjB6OESyNFg>
A431 MUTDfZRwfG:6aXOgRZN{[Xl? MYe3NkBp MXXDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDBOFMyKGOnbHzzJI93\XKneIDy[ZN{cW6pIFXHSnIhf2m2aDDJR|UxKG:oIESuNkDPxE1? NVq0NYI1OjFyOEC2Nlk>
A549 MnjOR5l1d3SxeHnjJGF{e2G7 NH;Ub2E4OiCq MUDDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDBOVQ6KGOnbHzzJI93\XKneIDy[ZN{cW6pIFjERWMhf2m2aDDJR|UxKG:oIEGuPEDPxE1? MX2yNVA5ODZ{OR?=
CAL27 NUnIPWRGS3m2b4TvfIlkKEG|c3H5 NYq0PWV[PzJiaB?= NIe0d3pEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBESUx{NzDj[YxteyCxdnXy[ZhxemW|c3nu[{BGT0[UIIfpeIghUUN3MDDv[kA{NjJizszN NWD5PWMxOjFyOEC2Nlk>
HeLa M4PkfmN6fG:2b4jpZ{BCe3OjeR?= MmnyO|IhcA>? MoO1R5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gTIVN[SClZXzsd{BwfmW{ZYjwdoV{e2mwZzDISGFEKHerdHigTWM2OCCxZjCxMlUh|ryP NYPWNo1sOjFyOEC2Nlk>
Sf21 NF7SfnNMcW6jc3WgRZN{[Xl? MnTuN{Bp NFWyNoNKdmirYnn0bY9vKG:oIF\sZYchfGGpZ3XkJIh2dWGwIILlZ49u[mmwYX70JGhFSUN6IHX4dJJme3OnZDD3bZRpKEmFNUCgc4YhOS5{IN88US=> MYiyNVA5ODZ{OR?=
SKBR3 M33kd2N6fG:2b4jpZ{BCe3OjeR?= MXe3NkBp MmiyR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gV2tDWjNiY3XscJMhd3[ncnX4dJJme3OrbnegTGVTOiC5aYToJGlEPTBib3[gNk43KM7:TR?= NHOwboQzOTB6ME[yPS=>
SKOV3 M2jQRWN6fG:2b4jpZ{BCe3OjeR?= MV63NkBp NYq0SZpqS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hW0uRVkOgZ4VtdHNib4\ldoV5eHKnc4PpcochUEWUMjD3bZRpKEmFNUCgc4YhOi5{IN88US=> MoOzNlExQDB4Mkm=
COR-L23 NUTEeGJMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{Lh[lExKM7:TR?= MnnkO|IhcA>? M4\STGROW09? NICw[IVIUTVyPUGuNUDPxE1? NWrqVpZTOjFyOEC2OFc>
DU145 NUnzVXNyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkjHNVAh|ryP M2jYcFczKGh? M{PhfWROW09? MUTHTVUxRTFwMEWg{txO M2DvPFIyODhyNkS3
LoVo NWntUFhIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFfzSFcyOCEQvF2= M4\rcVczKGh? NGm4NZpFVVOR M{DDUGdKPTB;MT63JO69VQ>? M4W0OFIyODhyNkS3
MCR5-SV2 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVexNEDPxE1? M1XQTFczKGh? MWnEUXNQ NVmyZ|d7T0l3ME2yMlEh|ryP NVjsc3dyOjFyOEC2OFc>
HCT116 MlXnT4lv[XOnIFHzd4F6 MmP6N|Ah|ryP M1y5TlMxKGh? NHjIWllFVVOR MlPLTY5pcWKrdHnvckBw\iCKRFHDOkBie3Onc4Pl[EBieyCrbnT1Z5Rqd25ib3[gZYxxcGFvdIXieYxqdiCjY3X0fYxifGmxbh?= MVOyNVA5ODZ2Nx?=
HCT116 MmfKT4lv[XOnIFHzd4F6 NGXnbJc{OCEQvF2= M2HrWVMxKGh? MX7EUXNQ NUPqe4xlUW6qaXLpeIlwdiCxZjDISGFEOSCjc4Pld5Nm\CCjczDpcoR2[3Srb36gc4YhcGm|dH;u[UBJO0t7IHHj[ZR6dGG2aX;u M4TxXFIyODhyNkS3
U937 MVzLbY5ie2ViQYPzZZk> NHfuXZk2KM7:TR?= NUDDNm1COjRiaB?= NVi2cWdlTE2VTx?= Mn7DTY5pcWKrdHnvckBw\iCqaYP0c45mKGGlZYT5cJRz[W6|ZnXyZZNmKGG|c3Xzd4VlKGG|IHnuZ5Jm[XOnIH;mJIFk\XS7bHH0bY9vKG:oIHjpd5RwdmViSEOgZZQhUzl? M3PKWVIyOjl{NEmy
U937 MkGyT4lv[XOnIFHzd4F6 NVOze2xDPSEQvF2= MX[yOEBp MlfVSG1UVw>? MkTRTY5pcWKrdHnvckBw\iCqaYP0c45mKGGlZYT5cJRz[W6|ZnXyZZNmKGG|c3Xzd4VlKGG|IHnuZ5Jm[XOnIH;mJIFk\XS7bHH0bY9vKG:oIHjpd5RwdmViSEOgZZQhUzF6 NIWyPZYzOTJ7MkS5Ni=>
U937 MnrNT4lv[XOnIFHzd4F6 M3;kVlUh|ryP NEj1OYgzPCCq Mk\XSG1UVw>? Mlu0TY5pcWKrdHnvckBw\iCqaYP0c45mKGGlZYT5cJRz[W6|ZnXyZZNmKGG|c3Xzd4VlKGG|IHnuZ5Jm[XOnIH;mJJBidi2jY3X0fYxifGWmIHjpd5RwdmViSESgcIV3\Wx? NIK4e4ozOTJ7MkS5Ni=>
U937 NGXvW5FMcW6jc3WgRZN{[Xl? NVvQV2M{PSEQvF2= MonmNVUhdWmw M4T4dWROW09? M1X1VWlvcGmkaYTpc44hd2ZiaHnzeI9v\SCjY3X0fYx1emGwc3\ldoF{\SCjc4Pld5Nm\CCjczDpcoNz\WG|ZTDv[kBpcXO2b37lJGg{KGGlZYT5cIF1cW:wIHzleoVt MYeyNVI6OjR7Mh?=
A2780 M360Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4m4[lk3KGh? MnLFSG1UVw>? NFTRN45KSzVyPUGuOlIh|ryP Mn70NlE3OzR2M{C=
COLO205 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHna[Ww6PiCq NGS3V5NFVVOR MVLJR|UxRTJwMUKg{txO NIL2OW0zOTZ|NESzNC=>
Hep3B NVTWdndXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYDtc5VHPDhiaB?= MXfEUXNQ M3LrU2dKPTB;MT6yNUDPxE1? NG\4[5czOTdzMkG0Oi=>
GM11272 NIj3e4VHfW6ldHnvckBCe3OjeR?= NHTjV4kyODBibl2= MlzxO|IhcA>? MX7EUXNQ MmfwVoVi[3SrdnH0bY9vKG:oIF3lR5AzKG23dHHueEBmgHC{ZYPzbY9vKGG2IEGwJJRwKDFyMDDuUS=> NIrEbmkzOTh2MEexOi=>
CFBE41o MkL0T4lv[XOnIFHzd4F6 M{C1[|Uh|ryP MUDEUXNQ NX22XmltTG:5bjDy[Yd2dGG2aX;uJI9nKEiGQVO3JIF1KDBwMjD0c{A2KHWP NVXIRWkyOjF7OES5OVg>
CFBE41o NEnuWHFHfW6ldHnvckBCe3OjeR?= M1LobFEh|ryP NXr2SY5HOjRiaB?= NIDPNFlFVVOR NV3TbVZZWmW|dH;yZZRqd25ib3[gR2ZVWiCmZXz0ZWY2ODhibYX0ZY51KHS{YX\mbYNscW6pIITvJINmdGxic4Xy[oFk\SCjczDncJlkd2[xcn3z NYPD[mVKOjF7OES5OVg>
DU145 MnzET4lv[XOnIFHzd4F6 NX3CN5RNOi53IN88US=> Ml\RNlQhcA>? MYPEUXNQ MlL3TY5pcWKrdHnvckBw\iCKRFHDJIF{e2W|c3XkJIF{KHWycnXneYxifGmxbjDv[kBxOjG5YX[xJJBzd3SnaX6g[ZhxemW|c3nvci=> MlTHNlIzPjBzNk[=
DU145 NVfrXo1lU2mwYYPlJGF{e2G7 NWfzXIZjPSEQvF2= NYjhb4NOOjRiaB?= NIrJNZlFVVOR MYDJcohq[mm2aX;uJI9nKEiGQVOgZZN{\XO|ZXSgZZMhcGm|dH;u[UBJPCCjY3X0fYxifGmxbh?= MYWyNlI3ODF4Nh?=
DU145 NH3Sb2JMcW6jc3WgRZN{[Xl? MXy1JO69VQ>? M2rmd|I1KGh? M3LYfGROW09? NIS3T3lKdmirYnn0bY9vKG:oIFjERWMh[XO|ZYPz[YQh[XNiaHnzeI9v\SCKMzDofZBmemGlZYT5cIF1cW:w MoDiNlIzPjBzNk[=
786-0 M2nK[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXzob2l7Pi5{IN88US=> M3\KflczKGh? NITZb4lFVVOR NXHvSZJzT0l3ME2zMlIh|ryP NWrKSJpvOjJ2M{W2Olk>
A498 M1W1Vmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4nG[VYvOiEQvF2= NETFT204OiCq MY\EUXNQ MVHHTVUxRTFwNjFOwG0> M{nM[VIzPDN3Nk[5
A549/ATCC MmPIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXXib|RzPi5{IN88US=> MVS3NkBp NV;jcmFsTE2VTx?= NGn3TVVIUTVyPUGuOkDPxE1? M4nlUFIzPDN3Nk[5
ACHN MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXi2MlIh|ryP M{f4VlczKGh? MnvNSG1UVw>? M2L4emdKPTB;MT6zJO69VQ>? M3fYNVIzPDN3Nk[5
BT549 NHvvUJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHPCb2k3NjJizszN NFSzcYI4OiCq NGD4dnNFVVOR MoLnS2k2OD1zLkOg{txO MVeyNlQ{PTZ4OR?=
EKVX MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3zlV|YvOiEQvF2= NG\CZWw4OiCq MWXEUXNQ NF3JOIJIUTVyPUGuN{DPxE1? NV3iZlVlOjJ2M{W2Olk>
HCT15 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGHLPWk3NjJizszN MmHxO|IhcA>? M{n6NGROW09? NGPhN4NIUTVyPUKuOUDPxE1? MnHyNlI1OzV4Nkm=
HOP92 NVOyXohrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4ThU|YvOiEQvF2= MnPUO|IhcA>? NUnBcJplTE2VTx?= MojVS2k2OD12IN88US=> M1fzW|IzPDN3Nk[5
IGROV1 MlTmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX\YbGdYPi5{IN88US=> NVHhbFljPzJiaB?= NHnUSI9FVVOR NI\l[lhIUTVyPUGuN{DPxE1? NWTh[XQxOjJ2M{W2Olk>
LOXIMVI M3O2cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{PJWlYvOiEQvF2= MV:3NkBp NIfKbodFVVOR M3r6N2dKPTB;MTFOwG0> NXe0XZIxOjJ2M{W2Olk>
M14 NFvNRplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2LHPFYvOiEQvF2= NXTP[VZTPzJiaB?= NUjFVGxsTE2VTx?= MYLHTVUxRTFwMzFOwG0> M2izSFIzPDN3Nk[5
MALME-3M MnHTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXXKPGNTPi5{IN88US=> NYPkdGxDPzJiaB?= MU\EUXNQ NHnuUnVIUTVyPUCuN|Ih|ryP NWezfm1qOjJ2M{W2Olk>
MCF10A MoHzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnvIOk4zKM7:TR?= MUG0PEBp MYfEUXNQ MlrIS2k2OD17Lk[g{txO M4jscFIzPDN3Nk[5
MDA-MB-435 Mk[0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFv2T4M3NjJizszN M{nGNFczKGh? MkfMSG1UVw>? NVnC[FJWT0l3ME2wMlUh|ryP NVXheVlFOjJ2M{W2Olk>
MDA-MB-468 NHrzPHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkLYOk4zKM7:TR?= M2f3dFczKGh? NHv6NFZFVVOR NH7sUWNIUTVyPUCuOlMh|ryP NFHXelkzOjR|NU[2PS=>
MOLT4 NIfvcHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX;mSlJWPi5{IN88US=> NIjGTJU4OiCq MYnEUXNQ MmWwS2k2OD1yLkSg{txO NWDTemxZOjJ2M{W2Olk>
NCI-ADR-RES MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWHlT2hTPi5{IN88US=> NWro[JZpPzJiaB?= NHm5Z|BFVVOR MUHHTVUxRTBwMU[g{txO M13VPVIzPDN3Nk[5
NCI-H23 NXfCTnVHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2mwVFYvOiEQvF2= MUm3NkBp MVXEUXNQ MYLHTVUxRTFizszN M2nGPVIzPDN3Nk[5
NCI-H322M MlvKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mnv3Ok4zKM7:TR?= NVfreFJNPzJiaB?= MkGxSG1UVw>? NYn3c2RQT0l3ME2wMlc6KM7:TR?= MlfqNlI1OzV4Nkm=
NCI-H460 NFmzTGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4DFRlYvOiEQvF2= MoPLO|IhcA>? MkLrSG1UVw>? MnjiS2k2OD1yLke5JO69VQ>? M4faV|IzPDN3Nk[5
NCI-H522 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWH2dWJEPi5{IN88US=> MmC2O|IhcA>? MlPtSG1UVw>? NWLyU5hGT0l3ME2wMlUh|ryP NW\0TW1zOjJ2M{W2Olk>
OVCAR3 NFjGO|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWLNW4NnPi5{IN88US=> NG\Bb|M4OiCq NVG3W2NjTE2VTx?= MYrHTVUxRTFwMzFOwG0> M3rhTVIzPDN3Nk[5
OVCAR4 NX\XOnFwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmLROk4zKM7:TR?= NHHMdI44OiCq NF7xRXZFVVOR MWHHTVUxRTRizszN NITPdHQzOjR|NU[2PS=>
OVCAR5 M165c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4fN[VYvOiEQvF2= M3v1VVczKGh? NFXpWYVFVVOR MmjkS2k2OD1yLke5JO69VQ>? MYeyNlQ{PTZ4OR?=
OVCAR8 M4T2SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmrqOk4zKM7:TR?= Ml3uO|IhcA>? M2\mZmROW09? NWHCOJk4T0l3ME2wMlUh|ryP MUOyNlQ{PTZ4OR?=
RXF393 M1O5PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4\URlYvOiEQvF2= NVy2WFBRPzJiaB?= NE\QbIZFVVOR Mn\KS2k2OD1zLkOg{txO M4\NUVIzPDN3Nk[5
SF268 NE\qZ4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYDzPHduPi5{IN88US=> NWjvcXVlPzJiaB?= MVjEUXNQ MlnCS2k2OD1zLk[g{txO MWSyNlQ{PTZ4OR?=
SF295 NGfXSZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWjBXWt6Pi5{IN88US=> MmG1O|IhcA>? MkPGSG1UVw>? MkLRS2k2OD1zLk[g{txO NVn5bHAzOjJ2M{W2Olk>
SF539 NGPnb5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3v4c|YvOiEQvF2= Mnj5O|IhcA>? NHy2RlRFVVOR Ml76S2k2OD1{IN88US=> NIW0fYYzOjR|NU[2PS=>
SK-MEL-2 NUTrTpBpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWXteYd3Pi5{IN88US=> NETIdpo4OiCq NGSxb3hFVVOR M1:2dGdKPTB;MT6zJO69VQ>? MWeyNlQ{PTZ4OR?=
SK-MEL-28 M4r2V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4\JOVYvOiEQvF2= MnnzO|IhcA>? M{nWSGROW09? M2\zVWdKPTB;MTFOwG0> NEPibHgzOjR|NU[2PS=>
SK-MEL-5 M3\3TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlLNOk4zKM7:TR?= NFPjWnU4OiCq NEnodGdFVVOR NUPTcIdxT0l3ME2wMlY{KM7:TR?= NYDPZnRTOjJ2M{W2Olk>
SKOV3 MlTSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1\uSFYvOiEQvF2= MX23NkBp M1HLemROW09? NH3xWpJIUTVyPUGg{txO M3jXb|IzPDN3Nk[5
SN12C Mlv2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MonlOk4zKM7:TR?= M1XhNlczKGh? M3ywOWROW09? M{n6W2dKPTB;MjFOwG0> NH\2R3gzOjR|NU[2PS=>
SNB19 NF3Ne2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4T5UVYvOiEQvF2= MUm3NkBp NU\ZTIozTE2VTx?= NHLKWmlIUTVyPUCuOlMh|ryP MYqyNlQ{PTZ4OR?=
SNB75 NIXoSVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUC2MlIh|ryP NXLZZmRiPzJiaB?= MlHtSG1UVw>? Mnv0S2k2OD1yLke5JO69VQ>? MmfmNlI1OzV4Nkm=
SR NWXJN4syT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MknVOk4zKM7:TR?= NX3EPXp{PzJiaB?= NUfVS3FRTE2VTx?= NU\rU|NUT0l3ME2wMlQh|ryP MmLXNlI1OzV4Nkm=
T47D MmrVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlLaOk4zKM7:TR?= NIWyPJY4OiCq MYPEUXNQ MVfHTVUxRTBwNTFOwG0> M{fJeFIzPDN3Nk[5
TK10 MorCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUK2MlIh|ryP NUfIbWZCPzJiaB?= M{TCc2ROW09? MkXtS2k2OD1yLk[zJO69VQ>? NWm0V5UyOjJ2M{W2Olk>
UACC257 NUnQdm5xT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2CxXlYvOiEQvF2= Mkf4O|IhcA>? MYfEUXNQ M{X2OGdKPTB;MD61JO69VQ>? MUWyNlQ{PTZ4OR?=
UACC62 NIPZWGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWXLOXQ1Pi5{IN88US=> NWT1WnZxPzJiaB?= M4jZN2ROW09? NXrYWopUT0l3ME2wMlQh|ryP Ml;aNlI1OzV4Nkm=
UO31 NV;1WWl3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYW2MlIh|ryP MXK3NkBp NVfZOJliTE2VTx?= MlvPS2k2OD1yLkWg{txO M1m5fVIzPDN3Nk[5
Hep3B NI\OT3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmC2OFghcA>? NI\v[IJFVVOR NFjXOoFIUTVyPUCuOlkh|ryP NYX5UZlXOjJ2M{m4OlM>
BE(2)-C NGrQdpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NW\2V3BoPzJiaB?= NHPDRWxFVVOR M4LCXmlEPzB;MjFOwG0> NV;yXpM{OjJ7M{KzNVY>
Bel7402 MoPtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoPEO|IhcA>? MlvxSG1UVw>? NWS2ZZkzT0l7ME2xO{DPxE1? MonkNlMxPjF|N{[=
Bel7404 NHzCW2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUG3NkBp NH61ZZZFVVOR NH7Pc2hIUTlyPUG4JO69VQ>? NVTqPFhtOjNyNkGzO|Y>
BGC823 NWPkcVJqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXO1OItnPzJiaB?= MW\EUXNQ M32x[mdKQTB;Nz61JO69VQ>? M{H2WVI{ODZzM{e2
MGC803 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH7Ld5Q4OiCq NEGyVJNFVVOR NXzsZoNWT0l7ME2xNE45KM7:TR?= M4q2dFI{ODZzM{e2
SGC7901 M2[xUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NET3Omc4OiCq MXPEUXNQ NIfNT3pIUTlyPUmuOEDPxE1? NWTlNJpnOjNyNkGzO|Y>
SKHEP1 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4j3cVczKGh? MYTEUXNQ NYLiOG45T0l7ME2xO{DPxE1? NEL4V|MzOzB4MUO3Oi=>
SMMC7721 NILROpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlTzO|IhcA>? NH3YNYhFVVOR MX;HTVkxRTJyIN88US=> M4nST|I{ODZzM{e2
NUGC3 NFP6PXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYjOW45yOTBizszN M4TuUmdKRTJwOUSg{txO M2CyU|I{OTZ|M{Oy
A2780 CisR NHX0dnhMcW6jc3WgRZN{[Xl? MXmxPEBp MVLJcohq[mm2aX;uJI9nKEiGQVOge4l1cCCLQ{WwJI9nKDBwNESg{txO MoP6NlMzPTJ4MEO=
CAL27 sens MX7LbY5ie2ViQYPzZZk> NF;ETFAyQCCq M1[5bWlvcGmkaYTpc44hd2ZiSFTBR{B4cXSqIFnDOVAhd2ZiMD6zOkDPxE1? MXSyN|I2OjZyMx?=
CAL27 CisR MYTLbY5ie2ViQYPzZZk> NEfzZnoyQCCq MlHTTY5pcWKrdHnvckBw\iCKRFHDJJdqfGhiSVO1NEBw\iByLk[xJO69VQ>? M{WweFI{OjV{NkCz
KYSE-510 CisR NIj3[VJMcW6jc3WgRZN{[Xl? MlrzNVghcA>? NVPpPIxJUW6qaXLpeIlwdiCxZjDISGFEKHerdHigTWM2OCCxZjCwMlU6KM7:TR?= NIPQRnkzOzJ3Mk[wNy=>
KYSE-510 sens NUfmTpRNU2mwYYPlJGF{e2G7 NFzwbGQyQCCq NVT4fJRjUW6qaXLpeIlwdiCxZjDISGFEKHerdHigTWM2OCCxZjCwMlch|ryP MkTnNlMzPTJ4MEO=
MDA-MB-231 sens NF;C[lJMcW6jc3WgRZN{[Xl? MkHwNVghcA>? NGDDNIhKdmirYnn0bY9vKG:oIFjERWMhf2m2aDDJR|UxKG:oIECuOlEh|ryP NXzpN3hPOjN{NUK2NFM>
MDA-MB-231 CisR NYTMVZdIU2mwYYPlJGF{e2G7 MWKxPEBp MXXJcohq[mm2aX;uJI9nKEiGQVOge4l1cCCLQ{WwJI9nKDBwNkGg{txO NIT2XmUzOzJ3Mk[wNy=>
ES2 NXy1Nm5iT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEnN[G81QCCq NUfXOG85TE2VTx?= NW\6O5dsUUN3ME2xNk44KM7:TR?= MXuyN|Q6OzR2OR?=
MDA-MB-231 M4fSNmtqdmG|ZTDBd5NigQ>? MVixNEDPxE1? M4DaelMxKG2rbh?= MoPrSG1UVw>? NHLVd5BKdmirYnn0bY9vKG:oIFjERWMz[Q>? MUKyN|Q6OzR2OR?=
MDA-MB-231 NHTzN2dMcW6jc3WgRZN{[Xl? NXfRfY5HOSEQvF2= MYCyOEBp MWTEUXNQ NYP1VmF5UW6qaXLpeIlwdiCxZjDISGFEPiCjc4Pld5Nm\CCjczDhZ4V1gWyjdHnvckBt\X[nbIOgc4YhfHWkdXzpci=> M3PpTlI{PDl|NES5
HS68 NHjk[4FEgXSxdH;4bYMhSXO|YYm= MljPNVAh|ryP MnfQO|IhcA>? NXnl[JVnTE2VTx?= NV6ySXpDUUN3ME20MlYh|ryP MX[yN|U4ODV2Mh?=
MEF MWHDfZRwfG:6aXOgRZN{[Xl? NGXDeHIyOCEQvF2= NYXZZWU3PzJiaB?= MWLEUXNQ MWLJR|UxRTRwNDFOwG0> M1XKfFI{PTdyNUSy
BGC823 MmXiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlzoSG1UVw>? NI\oboFIUTVyPUOuNFkh|ryP MXKyN|YxOTdyNh?=
High5 NGfxenZMcW6jc3WgRZN{[Xl? NVfrPGpFOjRiaB?= MljVTY5pcWKrdHnvckBw\iCqdX3hckBz\WOxbXLpcoFvfCCKRFHDOkB4cXSqIFnDOVAhd2ZiMD6wPUDPxE1? NGe3WHQzOzZyMkWyNy=>
High5 M4r6bGtqdmG|ZTDBd5NigQ>? NVLOfYpNOjRiaB?= MmrITY5pcWKrdHnvckBw\iCqdX3hckBz\WOxbXLpcoFvfCCKRFHDNUB4cXSqIFnDOVAhd2ZiMD6xNkDPxE1? NUnkblFlOjN4MEK1NlM>
High5 M{D6cmtqdmG|ZTDBd5NigQ>? MWeyOEBp NGq4cGlKdmirYnn0bY9vKG:oIHj1cYFvKHKnY3;tZolv[W62IFjERWM{KHerdHigTWM2OCCxZjCwMlE4KM7:TR?= M4S1WFI{PjB{NUKz
A549 MoWzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEnY[4xFVVOR Mlq3TWM2OD1zLkC3PUDPxE1? Mme0NlM3PDR{MUC=
HCT116 MlftS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnnNSG1UVw>? MnTmTWM2OD1yLke1O{DPxE1? NGfkNWozOzZ2NEKxNC=>
K562 NVzSN5JnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV7udXpvTE2VTx?= M{TvS2lEPTB;MD62OFUh|ryP NXThSoRLOjN4NESyNVA>
GBC-SD MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHXRflA2KM7:TR?= M2DKcVczKGh? M17PS2ROW09? M{X1XWlEPTB;MUSuPEDPxE1? NYXFS5pQOjN5MEeyOlA>
HGC27 NILDWJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX;5bos2PSEQvF2= NXzSbXV2PzJiaB?= MYHEUXNQ MWPJR|UxRTVwNDFOwG0> MljQNlM4ODd{NkC=
HL60 NWrsXmRwU2mwYYPlJGF{e2G7 MkTROUDPxE1? NVvsd41JOjRiaB?= M4DvN2ROW09? NHH4NnBKdmirYnn0bY9vKG:oIFjERWM> NFuyfVAzOzdyN{K2NC=>
Vero NVrxZ2hpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWXXdpBSPzJiaB?= MXvEUXNQ MorjTWM2OD1yLkmg{txO NHq1RoQzOzd6NkS1Ni=>
NCI60 NH\ZR4FEgXSxdH;4bYMhSXO|YYm= NFj0dXU1QCCq MlXoSG1UVw>? MnK0S2k:OC53MzFOwG0> M33IbFI1ODF3M{K3
SW620 NIrBUFdEgXSxdH;4bYMhSXO|YYm= NXjKdW1lPDhiaB?= M3z5[2ROW09? NV65W2ZzT0l;MD61OEDPxE1? NWrPcGNOOjRyMUWzNlc>
U251 NXLGT2twS3m2b4TvfIlkKEG|c3H5 M{PpXlQ5KGh? M3fNPWROW09? NYr5N3puT0l;MT61N{DPxE1? MVSyOFAyPTN{Nx?=
KM12 M1fKRmN6fG:2b4jpZ{BCe3OjeR?= M3nSZVQ5KGh? M2[5NWROW09? MXXHTV0yNjh6IN88US=> M32weFI1ODF3M{K3
Hs578T NXX6SGwxS3m2b4TvfIlkKEG|c3H5 MnzCOFghcA>? NFjhOY9FVVOR NETESYZIUT12LkizJO69VQ>? MX6yOFAyPTN{Nx?=
MDA-MB-231 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX20PEBp MoDzTWM2OD1yLkG2JO69VQ>? MWOyOFA6PTBzNh?=
MCF7 NX\wToFFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1zjO|Q5KGh? MWXHTV0xNjR3IN88US=> NXvh[Yp1OjRzMUm1OVU>
MDA-MB-435 NFnzXZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF2x[mM1QCCq Mn71S2k:OC56ODFOwG0> NX\yZZc5OjRzMUm1OVU>
AsPC1 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGHiW5I{OCEQvF2= M2G5TlQ5KGh? NX6ybYkxTE2VTx?= M{n5bGlEPTB;Mz62OkDPxE1? M4\uT|I1OTh3M{e4
Jurkat E6.1 NIjBeI5McW6jc3WgRZN{[Xl? M2fqTFIhcA>? MnnnSG1UVw>? M1u3[WlvcGmkaYTpc44hd2ZiSFTBR|Qhf2m2aDDJR|UxKG:oIECuNFQh|ryP M1HyU|I1OjZzOE[y
KG1 M2PjWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnLtOFghcA>? NYLk[po2UUN3ME2xMlE2KM7:TR?= NYruOFVDOjR3MkWwNFM>
HEL NFe0OGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnLZOFghcA>? NGPlc3dFVVOR M3vLUGlEPTB;MD60PUDPxE1? MXSyOFY6PDB3NR?=
HSC3 MULDfZRwfG:6aXOgRZN{[Xl? NF;FcVUyOiCq NF6zSYRFVVOR MknPTWM2OD1yLkexJO69VQ>? NGjNdpgzPDd4NkW2NC=>
HT-29 MoCzR5l1d3SxeHnjJGF{e2G7 NXPNVWwzOTJiaB?= MnruSG1UVw>? NF;jUlJKSzVyPUCuO|Ih|ryP NIfxeWUzPDd4NkW2NC=>
KB NGfHdplEgXSxdH;4bYMhSXO|YYm= MWSxNkBp M175XWROW09? M1f6VWlEPTB;MD63OUDPxE1? MYqyOFc3PjV4MB?=
H460 MkL3R5l1d3SxeHnjJGF{e2G7 MWixNkBp NV[5U4xoTE2VTx?= MmW5TWM2OD1yLkiyJO69VQ>? NGDxXJAzPDd4NkW2NC=>
MONE1 MVnDfZRwfG:6aXOgRZN{[Xl? MVuxNkBp MV\EUXNQ M1rMO2lEPTB;MT6xPEDPxE1? NGfmeHczPDd4NkW2NC=>
MKN45 MWfDfZRwfG:6aXOgRZN{[Xl? NGPVZ3UyOiCq NXLoZodRTE2VTx?= MmHLTWM2OD1zLkK1JO69VQ>? M3fHVFI1PzZ4NU[w
TSGH MmrVR5l1d3SxeHnjJGF{e2G7 MWKxNkBp NFS1cZNFVVOR M1HDVGlEPTB;Mj6wPUDPxE1? MXOyOFc3PjV4MB?=
HL60 MnniS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkXRO|IhcA>? NX3aN3lNTE2VTx?= MoHnS2k2OD1yLkmzJO69VQ>? MXyyOFkxODVyMB?=
HEK293 NWf5[ZRPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYq3NkBp NXv5bYZETE2VTx?= M4LhUWdKPTB;MUOg{txO NXTKOYxuOjR7MEC1NFA>
Jurkat Mk\5R5l1d3SxeHnjJGF{e2G7 M4rNTFExOCEQvF2= NX;DNVNNPzJiaB?= NUjnSWZ1T0l3ME2wMlkh|ryP NInaSmgzPDlyMEe0Ny=>
GM15850 M{LK[mtqdmG|ZTDBd5NigQ>? M1;1b|IvPSEQvF2= M1O2Xlk3KGh? MnTkSG1UVw>? M{WzS4Rw\XNibn;0JIlvcGmkaYSgTGRCSyCjc4Pld5Nm\CCjczDpcoNz\WG|ZTDpckBpcXO2b37lJGg{KGy7c3nu[UAyPCCjY3X0fYxifGmxbjDv[kBHYE5iZ3Xu[S=> NHPSc5AyPjl{MUO2Oy=>
GM15850 NFfDTYVMcW6jc3WgRZN{[Xl? MXqyMlUh|ryP M4X3dlk3KGh? MlLFSG1UVw>? NH;PR4xld2W|IH7veEBqdmirYnn0JGhFSUNiYYPz[ZN{\WRiYYOgbY5kemWjc3WgbY4hcGm|dH;u[UBJPCCueYPpcoUhPSCjY3X0fYxifGmxbjDv[kBHYE5iZ3Xu[S=> MXqxOlkzOTN4Nx?=
GM15850 M3PoNWtqdmG|ZTDBd5NigQ>? MmTwNk42KM7:TR?= NHvJe3M6PiCq MXrEUXNQ M3i5WoRw\XNibn;0JIlvcGmkaYSgTGRCSyCjc4Pld5Nm\CCjczDpcoNz\WG|ZTDpckBpcXO2b37lJGg1KGy7c3nu[UAyOiCjY3X0fYxifGmxbjDv[kBHYE5iZ3Xu[S=> NEWwT4UyPjl{MUO2Oy=>
GM15850 MV7LbY5ie2ViQYPzZZk> M3TVT|IvPSEQvF2= M{PuWlk3KGh? MXPEUXNQ NFfpcJhld2W|IH7veEBqdmirYnn0JGhFSUNiYYPz[ZN{\WRiYYOgbY5kemWjc3WgbY4hcGm|dH;u[UBJOyCueYPpcoUhQSCjY3X0fYxifGmxbjDv[kBHYE5iZ3Xu[S=> M2HwOFE3QTJzM{[3
GM15850 NWXGR4Z6U2mwYYPlJGF{e2G7 MomyNk42KM7:TR?= NE[zRWg6PiCq MmH2SG1UVw>? MXzkc4V{KG6xdDDpcohq[mm2IFjERWMh[XO|ZYPz[YQh[XNiaX7jdoVie2ViaX6gbIl{fG:wZTDIOEBtgXOrbnWgPEBi[2W2eXzheIlwdiCxZjDGXG4h\2WwZR?= NGH4enMyPjl{MUO2Oy=>
GM15850 MlPyT4lv[XOnIFHzd4F6 Mnr1Nk42KM7:TR?= MkDiPVYhcA>? MoHtSG1UVw>? NWn3R5pU\G:nczDuc5QhcW6qaXLpeEBJTEGFIHHzd4V{e2WmIHHzJIlv[3KnYYPlJIlvKGirc4TvcoUhUDRibInzbY5mKDF4IHHj[ZR6dGG2aX;uJI9nKE[[TjDn[Y5m MlnsNVY6OjF|Nke=
GM15850 M4rnTmZ2dmO2aX;uJGF{e2G7 NX3BdVhlPSEQvF2= M4TUXVEzKGh? MVvEUXNQ NF3DS2Vp[XNibn:g[YZn\WO2IH;uJGZZViCvUl7BJIV5eHKnc4Ppc44> M2DkflE3QTJzM{[3
U937 MUTLbY5ie2ViQYPzZZk> Mly4OUDPxE1? NEPXWGQzPCCq MW\EUXNQ NGLjfmZp[XNibn:g[YZn\WO2IH;uJIFteGijIIT1ZpVtcW5iYXPleJlt[XSrb36= NGP1VIMyPzR2N{e1NC=>
U937 MWLLbY5ie2ViQYPzZZk> NXnIS4JvOSEQvF2= MVSyOEBp M3jnXmROW09? M3zXdYhieyCwbzDl[oZm[3Rib36gZYxxcGFidIXieYxqdiCjY3X0fYxifGmxbh?= NUnlWWg3OTd2NEe3OVA>
PANC1 NULPWllrTnWwY4Tpc44hSXO|YYm= MnLRNUDPxE1? M3GwbVI1KGh? M4HvTIRw\XNibn;0JIlv[3KnYYPlJIlvKHB{N3vpdFEh\2WwZTDlfJBz\XO|aX;u NEPCZ2cyPzV6OEe0OC=>
PANC1 NV;0NFM2TnWwY4Tpc44hSXO|YYm= NGjmSIQyKM7:TR?= MnzXOFghKGh? MkPO[I9meyCwb4SgbY5kemWjc3WgbY4heDJ5a3nwNUBo\W6nIHX4dJJme3Orb36= NVP2O2F{OTd3OEi3OFQ>
Caco-2 MYLGeY5kfGmxbjDBd5NigQ>? NVqye4JtPSEQvF2= M4Tu[FI1KGh? NUGwRYNMTE2VTx?= Ml3Z[I9meyCwb4SgbY5lfWOnIGCyNXdCTjFiZ3Xu[UBmgHC{ZYPzbY9v NH7OcG0zODF2M{i0NC=>
SCC4 NILoR4hHfW6ldHnvckBCe3OjeR?= NILuUWUyKM7:TR?= NF;UZVAyOCCvaX6= Ml3mSG1UVw>? NEnHbHlp[XNibn:gZYdwdmm|dDDhZ5Rqfmm2eTDheEBXTFJiYYPz[ZN{\WRiYYOgbY5lfWO2aX;uJI9nKEO\UEK0JIdmdmViZYjwdoV{e2mxbh?= NIDsXHIzODR3MkKyOS=>
A549 NYn3NmlsTnWwY4Tpc44hSXO|YYm= MoDMOUDPxE1? M2jmd|MhcA>? NYnlUWJETE2VTx?= MojC[I9meyCwb4SgbY5lfWOnIHH1eI9xcGGpeTDhd5Nme3OnZDDhd{BqdmO{ZXHz[UBqdiCOQ{PJTS=> MYiyNFg2PTJyOB?=
HCT116 Mlz0T4lv[XOnIFHzd4F6 MWKwMlMh|ryP MlrqN|AhcA>? NEfLNHlFVVOR MVrkc4V{KG6xdDDpcohq[mm2IFjERWMyKGG|c3Xzd4VlKGG|IHnu[JVkfGmxbjDv[kBpcXO2b37lJGg{UzliYXPleJlt[XSrb36= MoDUNlExQDB4NEe=
HepG2 MlnESpVv[3Srb36gRZN{[Xl? MlvYNVAh|ryP NGrveW4zPCCq MmH0SG1UVw>? MV7kc4V{KG6xdDDpcoR2[2ViYYDvdJRwe2m|IHHzd4V{e2WmIHHzJIh6eGW{YXPleJlt[XSrb36gc4YheDV| M3Syd|IyPTR6NUiy
GM11272 M2GxfmZ2dmO2aX;uJGF{e2G7 MWGwMlEh|ryP M3LQOVczKGh? MWTEUXNQ MVvkc4V{KG6xdDDy[YFkfGm4YYTlJG1mS3B{IH31eIFvfCCneIDy[ZN{cW:w Mnu5NlE5PDB5MU[=
MDA-MB-231 NEDyT21McW6jc3WgRZN{[Xl? NHf3R5kyOCEQvF2= MmfFOUBucW5? NWjGc4xGTE2VTx?= MYHkc4V{KG6xdDDpcohq[mm2IFjERWMz[Q>? NH34RYgzOzR7M{S0PS=>
MDA-MB-231 NUPab3I3U2mwYYPlJGF{e2G7 NELlUFIyKM7:TR?= NUK4OXg3OjRiaB?= MmHDSG1UVw>? NFLsS5hld2W|IH7veEBqdmirYnn0JGhFSUN4IHHzd4V{e2WmIHHzJIFk\XS7bHH0bY9vKGyndnXsd{Bw\iC2dXL1cIlv NHG2TXIzOzR7M{S0PS=>
K562 M3zSNGtqdmG|ZTDBd5NigQ>? MVfkc4V{KG6xdDDpcohq[mm2IFjERWM> NVW5WG1zOjN3OUGxNVE>
Jurkat MVfDfZRwfG:6aXOgRZN{[Xl? MYmyNEDPxE1? NHvRe|M4OiCq NXzWdW97TE2VTx?= MXzuc{BkgXSxdH;4bYNqfHliYYPz[ZN{\WRiYYOg[5Jwf3SqIHnubIljcXSrb36= MWmyOFMxPDN2OB?=
HCT116 MXjBdI9xfG:|aYOgRZN{[Xl? MmrPN{DPxE1? M2\pOlI1KGh? NHr3cJFFVVOR NGCzXFhld2W|IH7veEBqdmS3Y3WgZZBweHSxc3nzJIF{e2W|c3XkJIF{KGmwY4LlZZNmKGmwIIC1N{Bxem:2ZXnuJIxmfmWu M{XDUlI1PzZ4NU[w
KASUMI-1 NIPDcnFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWLJR|UxRTl7LkG3JI5O MULTRW5ITVJ?
KARPAS-45 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{nse2lEPTB;MUezMlg6KG6P MXTTRW5ITVJ?
BHT-101 Ml2zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYrJR|UxRTJ2ND6xPEBvVQ>? NIe1SWtUSU6JRWK=
H9 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2XL[mlEPTB;MkW1MlA1KG6P NUnDRnRVW0GQR1XS
PA-1 NFr6SYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYrJR|UxRTJ6Nj6yOkBvVQ>? MoTWV2FPT0WU
NEC8 NY\ZUYdpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3\uUWlEPTB;Mki5MlM5KG6P Moj3V2FPT0WU
MHH-PREB-1 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoXITWM2OD1{OUSuOVMhdk1? Mn7xV2FPT0WU
NB7 MlfwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MY\JR|UxRTN2NT63OEBvVQ>? MonnV2FPT0WU
A3-KAW MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVXubW9kUUN3ME20NFAvPTlibl2= MlLSV2FPT0WU
NB69 MoH5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYDJR|UxRTRzMT63NUBvVQ>? NWCzUllLW0GQR1XS
EoL-1-cell MmPWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mnv1TWM2OD12NUSyOUBvVQ>? MYnTRW5ITVJ?
CHP-212 MofUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFHROohKSzVyPUS1O{42OyCwTR?= MlLWV2FPT0WU
C2BBe1 NF;oUYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmjJTWM2OD12N{KuNVkhdk1? MmTTV2FPT0WU
697 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGnYVINKSzVyPUS3N{41OSCwTR?= M4f5WHNCVkeHUh?=
BCPAP MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUTlfIRKUUN3ME21NFEvPDJibl2= M4fVfHNCVkeHUh?=
L-363 NH32bIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEfTe3JKSzVyPUWwN{4yKG6P M3nLTHNCVkeHUh?=
ES8 NXnqd25TT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV\JR|UxRTV{Mz61N{BvVQ>? NFnINZdUSU6JRWK=
BE-13 NVHMWoFsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1TaSmlEPTB;NUK2Mlk3KG6P NYfQWGVsW0GQR1XS
CTB-1 M{Cxe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4i2U2lEPTB;NUO3MlkzKG6P Mn7TV2FPT0WU
HD-MY-Z MlL4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGHX[IhKSzVyPUWzPE4yOyCwTR?= MXnTRW5ITVJ?
NKM-1 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2f2cWlEPTB;NUS0MlI4KG6P MX7TRW5ITVJ?
NCI-H720 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVfJR|UxRTV4MD6xPEBvVQ>? NHfiepRUSU6JRWK=
KY821 NG\5S3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnfLTWM2OD13NkOuNlUhdk1? NGe1N2xUSU6JRWK=
OVCAR-5 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{C5dWlEPTB;NUe2MlEyKG6P NEPZd2ZUSU6JRWK=
CTV-1 Ml7VS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV7JR|UxRTV6MT61OkBvVQ>? Ml7lV2FPT0WU
P12-ICHIKAWA Mk\JS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M37MZWlEPTB;NUm2MlUyKG6P NHezdpFUSU6JRWK=
DB Mor4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlziTWM2OD13OUiuOVchdk1? NVe4O295W0GQR1XS
CHL-1 Mlr0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIi2PIpKSzVyPU[0Nk4xQCCwTR?= NHe2XJFUSU6JRWK=
A4-Fuk NX\EfJFOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXzJR|UxRTZ2ND65NUBvVQ>? NYHLPWUyW0GQR1XS
MV-4-11 NFvxRo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXrJR|UxRTZ3OT6xJI5O MXPTRW5ITVJ?
RPMI-8226 M1nIdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3vJeWlEPTB;Nke4MlE5KG6P NIq5TGhUSU6JRWK=
NB14 MoTtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYDJR|UxRTZ7Nj65OUBvVQ>? M4XvNXNCVkeHUh?=
DOHH-2 MoHxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoL1TWM2OD15ME[uOlghdk1? MkfPV2FPT0WU
D-423MG NWnocYlsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXrJR|UxRTdyNj64PUBvVQ>? NITHfI5USU6JRWK=
D-283MED M{j5TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1XMbmlEPTB;N{G0MlE1KG6P NITtNZdUSU6JRWK=
ES1 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2jTN2lEPTB;N{K0MlQhdk1? NUfSfoVoW0GQR1XS
GOTO M4XGemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{PWT2lEPTB;N{K5MlEzKG6P M4m0fXNCVkeHUh?=
NCI-H209 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml7QTWM2OD15MkmuPUBvVQ>? M{nHWnNCVkeHUh?=
MOLT-13 Ml7NS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{DYeGlEPTB;N{O4Mlk5KG6P M{PpSnNCVkeHUh?=
ATN-1 Ml3rS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHvVPYZKSzVyPUe0NE4zQCCwTR?= NWT5PFV2W0GQR1XS
DU-4475 NYHM[2xGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXnRWZRWUUN3ME23OVEvQTFibl2= MUDTRW5ITVJ?
NB10 M1XsWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mnu0TWM2OD15NUGuPVIhdk1? NUL0bY01W0GQR1XS
KG-1 NYLGSnRvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4DRb2lEPTB;N{e1MlQ2KG6P NYe0fm9NW0GQR1XS
MOLT-4 NXzyVJBST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn7jTWM2OD15OEeuOFYhdk1? Ml;4V2FPT0WU
TE-1 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MliyTWM2OD15OUGuNUBvVQ>? NHLNVJdUSU6JRWK=
SBC-1 NWSzZ5VVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NI\zWJhKSzVyPUe5N{45PCCwTR?= NG\T[otUSU6JRWK=
HEL MmXVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHyzOmJKSzVyPUiwOk4xQCCwTR?= M13ibXNCVkeHUh?=
SK-MEL-2 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV\YXlBtUUN3ME24NFkvPDRibl2= NIHqSXVUSU6JRWK=
KU812 M1jpWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn3BTWM2OD16MUOuNUBvVQ>? MkTiV2FPT0WU
RPMI-8866 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3z0TGlEPTB;OEGzMlY4KG6P NECxeFFUSU6JRWK=
ALL-PO MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX7JR|UxRThzND62OkBvVQ>? M3n1dnNCVkeHUh?=
LU-139 NH;0dndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH7NfIpKSzVyPUiyNk45PiCwTR?= NI[3SVBUSU6JRWK=
RS4-11 NVfRfFVbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4nPNmlEPTB;OEOyMlQ2KG6P NVfOdFdWW0GQR1XS
EW-18 NIfQVZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4n5U2lEPTB;OEOyMlk3KG6P NVW1VHpxW0GQR1XS
P30-OHK MoTjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWXJR|UxRTh|NT63JI5O M1XSXnNCVkeHUh?=
D-566MG M2HUb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NG\4R5pKSzVyPUizPE43OiCwTR?= MYLTRW5ITVJ?
HSC-4 NEPNZ5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkfCTWM2OD16NE[uOVEhdk1? MWjTRW5ITVJ?
QIMR-WIL MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXPpV|l[UUN3ME24OlIvODNibl2= NXnm[VQyW0GQR1XS
SW954 M2O3eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUCwS2NbUUN3ME24OlMvOTZibl2= MYHTRW5ITVJ?
HGC-27 NITjOpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmL2TWM2OD16N{KuN|Qhdk1? M1u0SXNCVkeHUh?=
HH NWPxTGNMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1HndmlEPTB;OEm0MlEzKG6P MVjTRW5ITVJ?
KE-37 NH\2RXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUK2OmtmUUN3ME24PVQvPjJibl2= NVfX[pVwW0GQR1XS
SK-N-DZ MmPoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnfCTWM2OD17MECuOFMhdk1? MX7TRW5ITVJ?
J-RT3-T3-5 NEOwO2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFTo[FNKSzVyPUmxNE41QSCwTR?= MmDNV2FPT0WU
A427 MoTxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVvucWtvUUN3ME25NlAvQDRibl2= M{HCS3NCVkeHUh?=
ECC10 NIPaXGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M17PPWlEPTB;OUS1Mlg4KG6P NHfTOZJUSU6JRWK=
EW-1 MkjKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXLqSZJzUUN3ME25OFcvOjZibl2= NXzkcXo5W0GQR1XS
MIA-PaCa-2 NXrJOpJJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIfRO|lKSzVyPUm0PU4yOiCwTR?= NYjaSIdOW0GQR1XS
HCC2218 MnTJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYn0UWJuUUN3ME25OVgvPDhibl2= NH73d3NUSU6JRWK=
HAL-01 MoDyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVzTe2VmUUN3ME25OlgvODRibl2= MnrvV2FPT0WU
RD M33O[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml;QTWM2OD17N{SuOFUhdk1? NUfleYUyW0GQR1XS
SK-N-AS M37TS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mk\6TWM2OD17OEiuNUBvVQ>? NXnXUZdPW0GQR1XS
ML-2 NInzbHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MofJTWM2OD1zLkCwOFA4KM7:TR?= NY\aZ5V{W0GQR1XS
MEL-HO Mo\IS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmPtTWM2OD1zLkCwOVgzKM7:TR?= NUfKeIU{W0GQR1XS
MS-1 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXruN4FIUUN3ME2xMlAxPjF5IN88US=> NWK1OZUyW0GQR1XS
NCI-SNU-1 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHPITmxKSzVyPUGuNFI{OzFizszN NYOyZmhqW0GQR1XS
8505C NF3pZ4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2j1VmlEPTB;MT6wNlM{OSEQvF2= NYj4dHZXW0GQR1XS
MN-60 MnHxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGDodGRKSzVyPUGuNFI3QCEQvF2= MmXNV2FPT0WU
SAS M3LLcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2rKfmlEPTB;MT6wOFA5OSEQvF2= NUn1Xpk1W0GQR1XS
EFM-19 Mo\DS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF;ucXVKSzVyPUGuNFQ5PzlizszN MYLTRW5ITVJ?
Ca9-22 NUnxe4NtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV3JR|UxRTFwMEWxNFch|ryP MoHwV2FPT0WU
NBsusSR MmTxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3\PSWlEPTB;MT6wOVE3PiEQvF2= NWnsNohEW0GQR1XS
NB13 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoLETWM2OD1zLkC1OVAyKM7:TR?= NV;mWJZCW0GQR1XS
SF295 M3WyOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYrJR|UxRTFwME[2NlQh|ryP M{TObHNCVkeHUh?=
U-2-OS NHXxe4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3LKWGlEPTB;MT6wO|kyOSEQvF2= Ml7CV2FPT0WU
NCI-H526 NXPKS443T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV6y[|V6UUN3ME2xMlA5OjlzIN88US=> MYDTRW5ITVJ?
KMOE-2 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIjnPFFKSzVyPUGuNFk1OjJizszN MUDTRW5ITVJ?
RCM-1 NF\qVGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnHRTWM2OD1zLkGyNVAzKM7:TR?= MULTRW5ITVJ?
MC116 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3j5bGlEPTB;MT6xN|YzOSEQvF2= MVrTRW5ITVJ?
NCI-H1092 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{jGbWlEPTB;MT6xOVQxPiEQvF2= MVTTRW5ITVJ?
EW-3 NGTEZllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUDJR|UxRTFwMUeyNVIh|ryP MlXBV2FPT0WU
HCT-116 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV\JR|UxRTFwMUe3OUDPxE1? MVvTRW5ITVJ?
MC-IXC NH73OlBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUfJR|UxRTFwMUe4PFEh|ryP NFXSOI9USU6JRWK=
LB1047-RCC NWD3emdzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXvTPZNvUUN3ME2xMlE5OzF{IN88US=> NWXyeVJsW0GQR1XS
VM-CUB-1 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1rVN2lEPTB;MT6xPVExQCEQvF2= NGGzUFVUSU6JRWK=
NB5 NH7UN4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3Oxb2lEPTB;MT6xPVg2PiEQvF2= MkizV2FPT0WU
SKG-IIIa MlzjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkHxTWM2OD1zLkKzOFY1KM7:TR?= M{PWe3NCVkeHUh?=
HO-1-N-1 NFTMXpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXP4bHJMUUN3ME2xMlI{QDN3IN88US=> MVTTRW5ITVJ?
EFO-27 NFPDe4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkTwTWM2OD1zLkK1NFQ{KM7:TR?= MX;TRW5ITVJ?
MHH-NB-11 M1\Gc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWXJR|UxRTFwMkizNlkh|ryP NIHrbI1USU6JRWK=
SW620 NWC3cFN3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2fJSmlEPTB;MT6yPVAyQCEQvF2= MV3TRW5ITVJ?
MOLT-16 NHn6U5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYjJR|UxRTFwMkm3PVch|ryP MUTTRW5ITVJ?
NTERA-S-cl-D1 M1rCemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHLJZ29KSzVyPUGuN|E4PjFizszN MkDFV2FPT0WU
VA-ES-BJ MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmnETWM2OD1zLkOyOFc4KM7:TR?= NV7acIRpW0GQR1XS
HCC1419 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFrU[FZKSzVyPUGuN|QxOjdizszN NUG1[2F4W0GQR1XS
NCI-H69 NGHTN4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVrleJd2UUN3ME2xMlM1OTF{IN88US=> MUfTRW5ITVJ?
DEL NEPOOZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV63PZdXUUN3ME2xMlM2OTZ{IN88US=> MofoV2FPT0WU
LXF-289 NVPZWWRTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYfJR|UxRTFwM{WyOEDPxE1? MWjTRW5ITVJ?
EW-11 MnrQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIDWOmVKSzVyPUGuN|YxOjZizszN NETUTGZUSU6JRWK=
KP-4 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH\hbVNKSzVyPUGuN|cxQDVizszN NUTYO2xGW0GQR1XS
NOS-1 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NI[0THFKSzVyPUGuOFEyQTRizszN NITNZlNUSU6JRWK=
SK-NEP-1 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUX1d5VqUUN3ME2xMlQyPjl|IN88US=> MnfBV2FPT0WU
LAMA-84 Mm\US5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWXJR|UxRTFwNEO5OFUh|ryP MUTTRW5ITVJ?
ES5 M4fXNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVrJR|UxRTFwNESzJO69VQ>? M1\ReXNCVkeHUh?=
HuO9 Ml7FS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH7XfZpKSzVyPUGuOFU{PjJizszN NGDWbnZUSU6JRWK=
COLO-684 MoTFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlLGTWM2OD1zLkS2NVE5KM7:TR?= NFzPNGpUSU6JRWK=
EW-24 MnL0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYTJR|UxRTFwNE[1N|Eh|ryP NW\6OY9[W0GQR1XS
BV-173 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHWwXoJKSzVyPUGuOFczQTFizszN NGiw[3lUSU6JRWK=
NCI-H1770 NEe2SldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4DnPGlEPTB;MT60PFU{PiEQvF2= NEnaeJRUSU6JRWK=
HuP-T4 NIX1TnFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWXJR|UxRTFwNEmzJO69VQ>? Mmm3V2FPT0WU
TYK-nu MoPsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYHKNo9OUUN3ME2xMlQ6QDVzIN88US=> M1jkeXNCVkeHUh?=
YH-13 M3fBRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmLGTWM2OD1zLkS5PFk1KM7:TR?= M3r5S3NCVkeHUh?=
H4 Mln5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV7pV4hYUUN3ME2xMlUxQTF{IN88US=> M37YNHNCVkeHUh?=
OVCAR-8 M{DMVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWn3O4FTUUN3ME2xMlU1PDd5IN88US=> Mn:0V2FPT0WU
NCI-H23 NEnCRnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4fjR2lEPTB;MT61OFY1PSEQvF2= M3GySHNCVkeHUh?=
ES7 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFXoTHRKSzVyPUGuOVQ4PzNizszN MlvuV2FPT0WU
COR-L88 NFn2W4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHj3PFRKSzVyPUGuOVY1OjRizszN NUnDNZdQW0GQR1XS
TI-73 NV3DZphCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUXJR|UxRTFwNUmwOkDPxE1? M3iyXXNCVkeHUh?=
RT-112 M4Hm[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4DlfGlEPTB;MT61PVI5PCEQvF2= NY\jVVlTW0GQR1XS
HuO-3N1 NIL3[3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFHKPXlKSzVyPUGuOVk{QDVizszN MUHTRW5ITVJ?
HC-1 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnqwTWM2OD1zLkW5PFY3KM7:TR?= NEHSbIpUSU6JRWK=
HT55 NEfYNY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2nRSGlEPTB;MT62OVE{OSEQvF2= MnrwV2FPT0WU
IA-LM MkDBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIHiTW5KSzVyPUGuOlkzPzhizszN MWXTRW5ITVJ?
EM-2 MoXpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHiyNVVKSzVyPUGuO|AxOTRizszN NVzXZm0zW0GQR1XS
MHH-ES-1 MmfjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3XjTmlEPTB;MT63NFQ{PSEQvF2= NFTDfG5USU6JRWK=
CAL-27 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF\WepRKSzVyPUGuO|A3OjFizszN NVO4bXdFW0GQR1XS
COLO-800 M1XrVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWfJR|UxRTFwN{GxO|kh|ryP MUPTRW5ITVJ?
HCE-T NHW3TGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXfJR|UxRTFwN{G1JO69VQ>? MnTkV2FPT0WU
CAMA-1 NITtbJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYnJR|UxRTFwN{G5O|Eh|ryP NX3UbGZ1W0GQR1XS
LOXIMVI NVjxc3ZrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M364RmlEPTB;MT63NlEyKM7:TR?= NHT3dHpUSU6JRWK=
NH-12 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWfJR|UxRTFwN{K2PVEh|ryP M2nWbnNCVkeHUh?=
TCCSUP NWHzSZZ{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1vsRWlEPTB;MT63NlgzQSEQvF2= NWTsTYlFW0GQR1XS
MDA-MB-361 NV;5WVNrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIrreXhKSzVyPUGuO|MyPTdizszN M3TSVnNCVkeHUh?=
EW-16 M{PDOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUXJR|UxRTFwN{SxNFch|ryP NV3uVphkW0GQR1XS
SNU-423 M2foSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYTTXph1UUN3ME2xMlc2QDJ5IN88US=> NEe5S|NUSU6JRWK=
Daoy MmXES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYjJR|UxRTFwN{[zNVkh|ryP MX7TRW5ITVJ?
ES4 NUfJcFNFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVn6bIFzUUN3ME2xMlc5PzRzIN88US=> MkjGV2FPT0WU
PFSK-1 Ml64S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NG\2b2lKSzVyPUGuPFA{PyEQvF2= NH3Rdm5USU6JRWK=
ES3 NXq4fGNsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NULZ[o1PUUN3ME2xMlgzPjhzIN88US=> Mn[yV2FPT0WU
ONS-76 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHiwWIhKSzVyPUGuPFI5QTdizszN M1fLZ3NCVkeHUh?=
JVM-3 NHfENWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX\6dYk5UUN3ME2xMlg2PDVzIN88US=> MkeyV2FPT0WU
OS-RC-2 MoTES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MknITWM2OD1zLki3NVUyKM7:TR?= Mn3GV2FPT0WU
COLO-320-HSR NH\xS5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkfaTWM2OD1zLki4NVk4KM7:TR?= M4HEZXNCVkeHUh?=
HN NGjZVXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHzFb5RKSzVyPUGuPFg4OjVizszN NHrjb5FUSU6JRWK=
HT M3Hrd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3rYV2lEPTB;MT64PFk1PyEQvF2= M4fISHNCVkeHUh?=
LoVo M3XVN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVLJR|UxRTFwOEm4NUDPxE1? MWPTRW5ITVJ?
CGTH-W-1 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH3PbXdKSzVyPUGuPFk6PDZizszN M1jUdnNCVkeHUh?=
NB6 NGHGPJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHTCWpVKSzVyPUGuPVEzQThizszN MX7TRW5ITVJ?
EW-22 NUW3fpRUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{O3[mlEPTB;MT65Nlg5PyEQvF2= M1y1[HNCVkeHUh?=
ES6 NVHPblhKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4CySWlEPTB;MT65N|Y{OSEQvF2= NF;UTIxUSU6JRWK=
SCC-15 NFHHS5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWfGSIR{UUN3ME2xMlk{QDF7IN88US=> MULTRW5ITVJ?
HL-60 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYH3PFN[UUN3ME2xMlk{QTB{IN88US=> MmCxV2FPT0WU
human HOP-92 NEfaT4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUDV[mp1UUN3ME2xMlk1ODZ3IN88US=> MlPtV2FPT0WU
SW626 NX;pZ4NlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3HQ[GlEPTB;MT65OFg6QSEQvF2= NVHq[FF7W0GQR1XS
HEC-1 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmCzTWM2OD1zLkm1N|Yh|ryP M1u1OXNCVkeHUh?=
LB2241-RCC M4[1eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1HMSGlEPTB;MT65PFI{OSEQvF2= MmPZV2FPT0WU
Ramos-2G6-4C10 M17FWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVvJR|UxRTFwOUm0PVMh|ryP MVfTRW5ITVJ?
A101D MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFfz[2hKSzVyPUKuNlA{ODNizszN Moe3V2FPT0WU
NCI-H446 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M13W[mlEPTB;Mj6wOFU6QSEQvF2= MkHsV2FPT0WU
SBC-5 NWTzZYpVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MW\JR|UxRTJwME[xOFch|ryP NXS5ZXRKW0GQR1XS
HOS MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWPIboZkUUN3ME2yMlA4PjV|IN88US=> MUPTRW5ITVJ?
K5 Ml\jS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoXLTWM2OD1{LkC3PFEyKM7:TR?= M3HweHNCVkeHUh?=
HLE NH3SN5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH3wfmdKSzVyPUKuNFg2OjlizszN M1vBbXNCVkeHUh?=
HSC-2 NWnOd3NCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3G0cGlEPTB;Mj6xNlg6QCEQvF2= M2DMTXNCVkeHUh?=
LCLC-97TM1 NVXmdnF1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFLRWXhKSzVyPUKuNVQ2QDNizszN NEHDPG9USU6JRWK=
DMS-273 MnPBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGnzSXlKSzVyPUKuNVQ5OzdizszN M2LaSXNCVkeHUh?=
TE-8 NVv0PIh6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4TyeWlEPTB;Mj6xOVc3PSEQvF2= MV3TRW5ITVJ?
DSH1 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXnRe5I4UUN3ME2yMlE3Ozl6IN88US=> NGDST25USU6JRWK=
CAL-51 M2[2b2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVnJR|UxRTJwMU[2PVkh|ryP M3jaXHNCVkeHUh?=
IST-SL1 M{\wZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{SzWmlEPTB;Mj6xOlg1PCEQvF2= NEnNXI9USU6JRWK=
GCT NWHZOIFmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHXzTINKSzVyPUKuNVc4PyEQvF2= MYrTRW5ITVJ?
SW948 NHrrPFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mli4TWM2OD1{LkG4OFU3KM7:TR?= MX7TRW5ITVJ?
NOMO-1 NEDwbnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIXWNYZKSzVyPUKuNVk{OTdizszN M4TJRXNCVkeHUh?=
C8166 M2HQNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHTvPYhKSzVyPUKuNlE{OzRizszN M3H6SHNCVkeHUh?=
OC-314 MmftS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYHJR|UxRTJwMkOyOVkh|ryP M2XYPHNCVkeHUh?=
CAL-39 Mo\yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYnJR|UxRTJwMkO2NlYh|ryP M1TGT3NCVkeHUh?=
MDA-MB-453 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mlz2TWM2OD1{LkK0Nlc2KM7:TR?= M4HJNnNCVkeHUh?=
A673 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIP3flFKSzVyPUKuNlU5PjJizszN M3LpPXNCVkeHUh?=
HTC-C3 MlrKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1\Ne2lEPTB;Mj6yOlg2KM7:TR?= Mk\DV2FPT0WU
NCI-H1666 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnftTWM2OD1{LkK4NVEyKM7:TR?= M1K3ZXNCVkeHUh?=
PSN1 NHPOe5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYnJR|UxRTJwMki5NVMh|ryP M3zKW3NCVkeHUh?=
GI-1 NIO2OJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFfwZmVKSzVyPUKuN|A2PDNizszN NIfQR4xUSU6JRWK=
HuH-7 MmS2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1ntT2lEPTB;Mj6zNFY{PyEQvF2= NHOyT5VUSU6JRWK=
JAR NFu1S21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mm\1TWM2OD1{LkOxPVg4KM7:TR?= NULU[mVxW0GQR1XS
5637 MnXoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUnZcmRpUUN3ME2yMlMzOTJ7IN88US=> NXOyZpEzW0GQR1XS
GB-1 M2PwOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2TsfGlEPTB;Mj6zNlM{PSEQvF2= M3P1NXNCVkeHUh?=
KP-N-YS M{L0W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUH4bppGUUN3ME2yMlMzPjF3IN88US=> MkLsV2FPT0WU
OAW-42 Mn3YS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mki3TWM2OD1{LkOzOFE3KM7:TR?= M1;KWnNCVkeHUh?=
8-MG-BA MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUHj[XRKUUN3ME2yMlM{QTB4IN88US=> MnftV2FPT0WU
RH-18 MlHoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnvOTWM2OD1{LkO1NFIzKM7:TR?= MlHEV2FPT0WU
NCI-H1155 M1rmXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnPJTWM2OD1{LkO2O|I2KM7:TR?= NInpNFdUSU6JRWK=
NB17 NV:wU4p[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV7MUFBWUUN3ME2yMlM5OjR|IN88US=> NVX4cpJIW0GQR1XS
NCI-H1437 Mk\oS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXLJR|UxRTJwNEG4O|Mh|ryP M1fRVnNCVkeHUh?=
SN12C NIrmb4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NI\0eFBKSzVyPUKuOFMzOTRizszN MUDTRW5ITVJ?
HSC-3 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYTNbIFwUUN3ME2yMlQ1PTB7IN88US=> MYjTRW5ITVJ?
GAMG NEXRfolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYrJR|UxRTJwNES1OlEh|ryP MUfTRW5ITVJ?
HT-1080 Mn\XS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVvJR|UxRTJwNES4OlQh|ryP MYnTRW5ITVJ?
A549 MoD5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3z6cWlEPTB;Mj60OFg6OyEQvF2= MnPUV2FPT0WU
KNS-62 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVvJR|UxRTJwNEWwOlEh|ryP NEfrdIxUSU6JRWK=
YKG-1 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYPOUnM1UUN3ME2yMlQ2PDN5IN88US=> M3XKU3NCVkeHUh?=
LU-134-A NYXFSZliT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1y0VGlEPTB;Mj60O|AxQCEQvF2= M2jVZXNCVkeHUh?=
FADU M2rKTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2KzUWlEPTB;Mj60O|E3OiEQvF2= MmTRV2FPT0WU
TGBC11TKB M{nJO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV7JR|UxRTJwNEexO|ch|ryP M1HCT3NCVkeHUh?=
HT-3 NUnYb5FuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1yxemlEPTB;Mj60PVU{PSEQvF2= M3XsXXNCVkeHUh?=
NCI-H2170 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1rwc2lEPTB;Mj61NFU1QSEQvF2= MX\TRW5ITVJ?
Mo-T M4q1R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2e0UWlEPTB;Mj61NFkzPyEQvF2= M13aW3NCVkeHUh?=
CCRF-CEM NE\PW2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUjUNZNiUUN3ME2yMlU{ODR|IN88US=> NYrkbHJ6W0GQR1XS
KU-19-19 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV2xOYFqUUN3ME2yMlU{PTF|IN88US=> M4XBTXNCVkeHUh?=
NCI-H1048 M1zpOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NULLOlVtUUN3ME2yMlU2ODJ3IN88US=> NXPmXXliW0GQR1XS
KOSC-2 MnPsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFzzVFVKSzVyPUKuOVYxPzZizszN MkS1V2FPT0WU
A431 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2DnVGlEPTB;Mj61OlM{PSEQvF2= NXj5PFdMW0GQR1XS
COR-L23 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn;kTWM2OD1{LkW4OVY3KM7:TR?= MljrV2FPT0WU
MKN28 NULQe2ZmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUPJR|UxRTJwNUmwN|ch|ryP MXfTRW5ITVJ?
22RV1 MornS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3PkVGlEPTB;Mj61PVI4PCEQvF2= M3zW[HNCVkeHUh?=
ABC-1 MmO0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{H0XWlEPTB;Mj62NFQ3KM7:TR?= NHja[ppUSU6JRWK=
NCI-H2126 NU\zTZJFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGTFbJdKSzVyPUKuOlA6QDRizszN M3PzWnNCVkeHUh?=
DoTc2-4510 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGfUbIVKSzVyPUKuOlIyQDVizszN MljNV2FPT0WU
SCC-4 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHjDdJpKSzVyPUKuOlMxOTJizszN MVnTRW5ITVJ?
NCI-H661 NGjOdm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWDJR|UxRTJwNkSwPFUh|ryP NU\YeIpZW0GQR1XS
RPMI-2650 MkXrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXTJR|UxRTJwNkSxOFMh|ryP MnjaV2FPT0WU
NCI-H510A M2\2[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoH1TWM2OD1{Lk[0OFI3KM7:TR?= MWnTRW5ITVJ?
BPH-1 NVTpfY5LT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlLaTWM2OD1{Lk[1PFUh|ryP MWLTRW5ITVJ?
M14 M1fRN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoTzTWM2OD1{Lk[2PVk{KM7:TR?= MWnTRW5ITVJ?
G-402 MoS0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2LZXmlEPTB;Mj63NFQ2OSEQvF2= MlrzV2FPT0WU
AsPC-1 MknaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUHSSGhqUUN3ME2yMlcyOTdizszN MoXqV2FPT0WU
NB12 M3T2VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2faVWlEPTB;Mj63NVcyKM7:TR?= NVXMfFQ2W0GQR1XS
SK-HEP-1 NXj2TIY1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NULKSYs1UUN3ME2yMlc1OzlzIN88US=> NIPFRXJUSU6JRWK=
U-266 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV\JR|UxRTJwN{exNlEh|ryP NFfiO2pUSU6JRWK=
AM-38 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4LHPGlEPTB;Mj63O|M2PSEQvF2= MYTTRW5ITVJ?
PC-14 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn7NTWM2OD1{LkiwOVEh|ryP MVPTRW5ITVJ?
EGI-1 NE[4V4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVPJR|UxRTJwOEG3OFMh|ryP MVzTRW5ITVJ?
LS-411N Mmq5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mlv1TWM2OD1{LkiyN|Mh|ryP M4HqSnNCVkeHUh?=
BFTC-905 NWXOZZZsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnzlTWM2OD1{Lki1OVI{KM7:TR?= M3\FcHNCVkeHUh?=
CaR-1 M{mwSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV7jTmFoUUN3ME2yMlg3KM7:TR?= MYfTRW5ITVJ?
NCI-H292 NFjTZoNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkjiTWM2OD1{Lki2OVk3KM7:TR?= NHj5V|hUSU6JRWK=
8305C NV\CZ2FqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFfwWXdKSzVyPUKuPFY3PDVizszN MXfTRW5ITVJ?
SNU-449 NYfIdXBGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUPRbW16UUN3ME2yMlg6OTh{IN88US=> NHLMXZRUSU6JRWK=
LCLC-103H M{Lwe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUnJR|UxRTJwOUC0N|gh|ryP NHLHU4lUSU6JRWK=
SW1573 NIPUOWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3HQeWlEPTB;Mj65OlA5OiEQvF2= M4XROHNCVkeHUh?=
MLMA NYr0TWhLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYTkXHhXUUN3ME2yMlk3PzF5IN88US=> MnWzV2FPT0WU
NCI-H1355 NIfnfJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYC4VGRKUUN3ME2zMlAxPzl4IN88US=> MXrTRW5ITVJ?
RMG-I NFX5UlNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHHPWIpKSzVyPUOuNFI2QTJizszN NXfwV3RzW0GQR1XS
BB65-RCC MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4TTcGlEPTB;Mz6wN|MyPCEQvF2= NVvMVGJQW0GQR1XS
PC-3 NFvMUWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn;vTWM2OD1|LkCzPFc1KM7:TR?= MXXTRW5ITVJ?
SF268 M4DHVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml;zTWM2OD1|LkC0OVI{KM7:TR?= NXf1c21kW0GQR1XS
NCI-H810 M{LRS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnrtTWM2OD1|LkC0PFI{KM7:TR?= NV:xVmlvW0GQR1XS
MEG-01 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4rrW2lEPTB;Mz6wOlE3PCEQvF2= M32zfXNCVkeHUh?=
SW13 M3HDS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3TKWmlEPTB;Mz6wO|g1PyEQvF2= NWXYTHRKW0GQR1XS
RH-1 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnTvTWM2OD1|LkGwNlc5KM7:TR?= NU\r[3RMW0GQR1XS
GT3TKB M3fMZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnLGTWM2OD1|LkGxNlg{KM7:TR?= MkniV2FPT0WU
TK10 MoHPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV\JR|UxRTNwMUO3NlQh|ryP MWLTRW5ITVJ?
T-24 NEPPVVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2ruRWlEPTB;Mz6xOVA4KM7:TR?= NHfqboVUSU6JRWK=
A498 NYPobllLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX3JR|UxRTNwMkC4O|Eh|ryP MnO1V2FPT0WU
GR-ST MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1SwRmlEPTB;Mz6yNlE{QSEQvF2= NWjzd|JDW0GQR1XS
LB2518-MEL Mm\4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF7UcJBKSzVyPUOuNlI{QThizszN MoTnV2FPT0WU
T47D NIrvR5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUDJR|UxRTNwMkO2Nlch|ryP NWjmSod2W0GQR1XS
NCI-H1651 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYPrZ2pkUUN3ME2zMlI1PjR2IN88US=> NHzTO4dUSU6JRWK=
EC-GI-10 MnnGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml;YTWM2OD1|LkK2NVU{KM7:TR?= MoCxV2FPT0WU
HT-29 NFzWNpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWe2[m92UUN3ME2zMlI3PjF2IN88US=> NUe3cld[W0GQR1XS
GI-ME-N NYnUUIQ{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWLm[486UUN3ME2zMlI6PTFzIN88US=> NFK5bHJUSU6JRWK=
SW756 NGLLTGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NI\OfHJKSzVyPUOuNlk3OjlizszN NYnsO3U3W0GQR1XS
RKO NYPIcGZqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYXJR|UxRTNwM{C3OVch|ryP MWnTRW5ITVJ?
NCI-H1563 NHHaTnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoT3TWM2OD1|LkOzNFE5KM7:TR?= MWjTRW5ITVJ?
DJM-1 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnnQTWM2OD1|LkO3Olc1KM7:TR?= NFrMUmtUSU6JRWK=
L-428 NIPYWVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4PRdmlEPTB;Mz60NFA1PSEQvF2= NGPpOZlUSU6JRWK=
NCI-H2122 M{fKSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV;rfVdOUUN3ME2zMlQyOzF{IN88US=> NWnKSXZmW0GQR1XS
Ca-Ski NIjvenlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml7rTWM2OD1|LkS1OFMh|ryP M4DTe3NCVkeHUh?=
639-V MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIDqOGFKSzVyPUOuOFYxPTdizszN MX\TRW5ITVJ?
SW1116 M1vNd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHXodmJKSzVyPUOuOFYzPjlizszN NXjYbJZSW0GQR1XS
DMS-114 NHzzfJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWjLUVh7UUN3ME2zMlQ4ODZ4IN88US=> Mn3lV2FPT0WU
MZ2-MEL NFS2TYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX7JR|UxRTNwNEe2PFEh|ryP MXzTRW5ITVJ?
COLO-829 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3e0c2lEPTB;Mz61NFA4OyEQvF2= NYXZRVF3W0GQR1XS
J82 NFzITZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NICwd5lKSzVyPUOuOVA2PyEQvF2= NF7vPY1USU6JRWK=
EW-13 NGPVfHFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYS1[XdxUUN3ME2zMlUzPTFizszN M4PzSXNCVkeHUh?=
RXF393 NX3ieGFGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{PtTGlEPTB;Mz61N|I6PCEQvF2= M3r0bHNCVkeHUh?=
CAL-62 NYPDTXJET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYjGdJRjUUN3ME2zMlU1PTF2IN88US=> MkDWV2FPT0WU
OCUB-M MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXvJR|UxRTNwNUS2OlUh|ryP NIW1eGlUSU6JRWK=
BT-474 Mn\ES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4LmdmlEPTB;Mz62N|MyKM7:TR?= NFTHOndUSU6JRWK=
KYSE-180 NUnDUmlwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYLaRnZ2UUN3ME2zMlY{Ozd{IN88US=> M1\FV3NCVkeHUh?=
NCI-H650 Mn\jS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4DkRWlEPTB;Mz62OFI5PyEQvF2= NHvq[o5USU6JRWK=
Detroit562 M1rwcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYGySWY5UUN3ME2zMlY2ODJ{IN88US=> NGrr[29USU6JRWK=
SW48 NEHUVFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVXJR|UxRTNwNkW2OVch|ryP NUXDcYdtW0GQR1XS
KYSE-450 NVH4OYFJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEPkN2JKSzVyPUOuOlg2QDJizszN NFPOeGFUSU6JRWK=
KYSE-510 NIi2XVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mof3TWM2OD1|LkeyNVgyKM7:TR?= MXHTRW5ITVJ?
GP5d NFOwVppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1HNW2lEPTB;Mz63Nlk2KM7:TR?= M3noU3NCVkeHUh?=
RPMI-7951 NXy2RXhLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEPyd3NKSzVyPUOuO|Q4OjNizszN NHS5NXlUSU6JRWK=
Becker MkjHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEXSfXRKSzVyPUOuO|UxOTJizszN Moe2V2FPT0WU
WM-115 M3vkWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmrTTWM2OD1|Lke4NVk2KM7:TR?= NUXWSGxEW0GQR1XS
G-401 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlHITWM2OD1|Lke5NFg2KM7:TR?= NWLkclVjW0GQR1XS
PANC-08-13 NXm1dVV1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NETLZ4FKSzVyPUOuO|k3ODJizszN MXHTRW5ITVJ?
SW982 NGCzcWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlTVTWM2OD1|LkiwOVUyKM7:TR?= NXrtSXdOW0GQR1XS
D-263MG MnfzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF7xcnRKSzVyPUOuPFIxPTFizszN NVHYSoo5W0GQR1XS
KM-H2 NITTPZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWDJR|UxRTNwOEK2NlQh|ryP NGrOUZRUSU6JRWK=
SK-MEL-3 M2XidWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlThTWM2OD1|LkiyPFQyKM7:TR?= NVjvTFZmW0GQR1XS
NCI-H1581 NF3UV3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2PmWGlEPTB;Mz64OFQ5QCEQvF2= M2DUeXNCVkeHUh?=
LS-123 M4eyXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF3YcnRKSzVyPUOuPFc6ODlizszN M3fqTXNCVkeHUh?=
CAKI-1 Ml7vS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3SzeWlEPTB;Mz64PVA2OiEQvF2= M4HpNnNCVkeHUh?=
MEL-JUSO M{TUTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYXJR|UxRTNwOEmxOVMh|ryP MnTSV2FPT0WU
HCE-4 MneyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NITlRYlKSzVyPUOuPVE3PjNizszN NH:3VFhUSU6JRWK=
TE-10 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NInJdWVKSzVyPUOuPVIxOSEQvF2= MUjTRW5ITVJ?
OVCAR-4 M{Ow[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWPJR|UxRTNwOUK4PFkh|ryP MkXlV2FPT0WU
ETK-1 NIPyTotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoriTWM2OD1|Lkm0OlM2KM7:TR?= NEO2Vo5USU6JRWK=
A2780 M1q0c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWq0NGJ1UUN3ME20MlA2QTZ4IN88US=> M{DyUnNCVkeHUh?=
LU-65 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4PuemlEPTB;ND6wO|Y{OyEQvF2= M3S5V3NCVkeHUh?=
BHY NGX2dItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{CwSGlEPTB;ND6xNlQ6PSEQvF2= Mmi2V2FPT0WU
COR-L105 MoryS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3zRdmlEPTB;ND6xN|A2OSEQvF2= NWK5PFBnW0GQR1XS
CAL-12T MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIrlOZhKSzVyPUSuNVMyODNizszN NFzifJZUSU6JRWK=
SCH MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3vad2lEPTB;ND6xOVc1OyEQvF2= M{X5[XNCVkeHUh?=
CW-2 Mn;oS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4r1RWlEPTB;ND6xPVAxOSEQvF2= MVPTRW5ITVJ?
HCC1806 NUnPUVlkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXuzb5Q{UUN3ME20MlIxOzF{IN88US=> NUfrU|Q2W0GQR1XS
KP-N-YN NFG1Z5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV;JR|UxRTRwMkC5Nlch|ryP M1HhWXNCVkeHUh?=
T98G MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX7JR|UxRTRwMkKxOVch|ryP MVTTRW5ITVJ?
CAL-54 M{nkUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVKySmR[UUN3ME20MlIzOzhzIN88US=> MnzOV2FPT0WU
CAL-33 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2DF[mlEPTB;ND6yN|A3PCEQvF2= NYiyUnRCW0GQR1XS
SNU-C2B MmnRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYLJR|UxRTRwMkS3Olkh|ryP MoHjV2FPT0WU
NUGC-3 NFPIUXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVjJR|UxRTRwMkW1NFUh|ryP NY\6OXJRW0GQR1XS
DOK MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MofLTWM2OD12LkK2OVk{KM7:TR?= MnnIV2FPT0WU
MMAC-SF NH:4UJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXW0VVRTUUN3ME20MlI3QDV7IN88US=> M3;sPXNCVkeHUh?=
KYSE-70 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXm4UZZrUUN3ME20MlI6OzRizszN MYLTRW5ITVJ?
A204 MlfvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mo\NTWM2OD12LkO1PFA{KM7:TR?= NH72e5hUSU6JRWK=
SCC-25 MlrWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1jHZWlEPTB;ND6zOVgyQSEQvF2= NEH3bVVUSU6JRWK=
EPLC-272H MmnlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHfuZ4NKSzVyPUSuN|g6PSEQvF2= M1P0fnNCVkeHUh?=
CAL-120 M1jqfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUXGSJFpUUN3ME20MlM5QTl{IN88US=> NWrxSoJUW0GQR1XS
LS-513 NG\JW|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUHWPG5yUUN3ME20MlQzOTl6IN88US=> M{HDenNCVkeHUh?=
CAPAN-1 NYHHZ4ozT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXLJR|UxRTRwNEKzPFIh|ryP M1;XenNCVkeHUh?=
ESS-1 NFP3[lBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEL0[XRKSzVyPUSuOFI4OjRizszN MUfTRW5ITVJ?
GMS-10 NYrCVWg4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEnqTpdKSzVyPUSuOFI5OTlizszN M1zwSXNCVkeHUh?=
NCI-N87 M{Dibmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX\JR|UxRTRwNUC4Olgh|ryP MnrEV2FPT0WU
HMV-II MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mk\jTWM2OD12LkWxO|Mh|ryP NHezSGRUSU6JRWK=
COLO-741 NUDpeXFST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXLJR|UxRTRwNUW5PVQh|ryP M1ixbXNCVkeHUh?=
MKN45 NInicnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml\PTWM2OD12LkW3O|MzKM7:TR?= MnnRV2FPT0WU
OAW-28 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2PhXWlEPTB;ND61PFM6QCEQvF2= NV\oenJKW0GQR1XS
OCI-AML2 NXrhb5lST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{KwW2lEPTB;ND62OVI{QCEQvF2= NGP2bWlUSU6JRWK=
MDA-MB-231 NUPwemNKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIDBS2ZKSzVyPUSuO|AzPDNizszN MWDTRW5ITVJ?
NCI-H1648 M13McWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXXJR|UxRTRwN{KyO|Mh|ryP M3fnV3NCVkeHUh?=
NCI-H1792 M1PZW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmTLTWM2OD12Lke2NVA4KM7:TR?= MYDTRW5ITVJ?
GCIY MnfES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUPCPYNnUUN3ME20Mlc4PDJ2IN88US=> MknnV2FPT0WU
Hs-578-T MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVLtcol[UUN3ME20Mlc4PjV3IN88US=> MmjDV2FPT0WU
SW962 NX:zcI9CT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVrJR|UxRTRwN{iwNVEh|ryP NWLFOYJUW0GQR1XS
NCI-H630 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4XBcWlEPTB;ND63PFA5OSEQvF2= MljHV2FPT0WU
786-0 MkXTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1i5WWlEPTB;ND63PFc4OyEQvF2= MVnTRW5ITVJ?
FTC-133 NHPXNm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVvJR|UxRTRwN{myOlMh|ryP MoPBV2FPT0WU
BT-20 M2Di[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4TkNmlEPTB;ND63PVQzQSEQvF2= NWm5dnBEW0GQR1XS
Mewo MmHkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWfJR|UxRTRwOEG3OFch|ryP M3nSN3NCVkeHUh?=
SW780 Mmn6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFG5ZW9KSzVyPUSuPFU4PjZizszN M2PqNXNCVkeHUh?=
OE33 NH60WnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mlq0TWM2OD12Lki3O|E{KM7:TR?= MonHV2FPT0WU
HCC1569 NWnYZYl1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn6xTWM2OD12Lki4OFU5KM7:TR?= M3rDeXNCVkeHUh?=
TE-6 NWmyVmdsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1j2d2lEPTB;ND65N|k4PyEQvF2= MWrTRW5ITVJ?
SK-N-FI M1n2PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmL4TWM2OD12Lkm0OFIyKM7:TR?= M3roe3NCVkeHUh?=
PANC-03-27 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mlr1TWM2OD12Lkm5PVYzKM7:TR?= M3vYNHNCVkeHUh?=
MCF7 Mn\yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX;JR|UxRTVwMEC3N|gh|ryP M2\XWHNCVkeHUh?=
UACC-257 NYTGcI0xT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWfaU3pJUUN3ME21MlAzQDR3IN88US=> MmXXV2FPT0WU
SW1088 NVHP[2ZET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mnz1TWM2OD13LkCyPVQ1KM7:TR?= MnnXV2FPT0WU
A704 M1j3Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3\lTWlEPTB;NT6wN|A3KM7:TR?= NU\DWJdCW0GQR1XS
A2058 MlnyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGPPU3JKSzVyPUWuNFU6ODhizszN NGCwVINUSU6JRWK=
Calu-3 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlTCTWM2OD13LkC2OFUzKM7:TR?= MYfTRW5ITVJ?
RERF-LC-MS M1PhPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH7sXoNKSzVyPUWuNFY6ODNizszN MY\TRW5ITVJ?
AU565 MoHrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NG[0eHpKSzVyPUWuNFk4ODJizszN NXHZR3hMW0GQR1XS
DMS-79 MkXDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkTNTWM2OD13LkGzPFg{KM7:TR?= NFLvdphUSU6JRWK=
DK-MG MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV3YUm5OUUN3ME21MlE5PDN6IN88US=> NULkNGNTW0GQR1XS
HuCCT1 M4myWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWjJR|UxRTVwMkO4OVYh|ryP M33xRnNCVkeHUh?=
HT-144 MkLXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUWwe5ljUUN3ME21MlI1QTh5IN88US=> M2PwTnNCVkeHUh?=
M059J MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3;HVmlEPTB;NT6yOVc3KM7:TR?= NFzGNpdUSU6JRWK=
COLO-792 Mmi1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYLJR|UxRTVwMk[zOVYh|ryP MnvXV2FPT0WU
SF539 NEiwNWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYryeotVUUN3ME21MlI3PjN{IN88US=> M{TBTXNCVkeHUh?=
SK-UT-1 NWrJPYMzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWfjbJl6UUN3ME21MlI4PzVzIN88US=> M4LVcXNCVkeHUh?=
NCI-H1703 MnHSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV3JR|UxRTVwM{W4NlYh|ryP NFXpWnlUSU6JRWK=
SW837 M4j2Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1jK[GlEPTB;NT6zO|g4QCEQvF2= MVzTRW5ITVJ?
U251 MnvmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVLJR|UxRTVwM{mwPVYh|ryP NFy0bWdUSU6JRWK=
SW1710 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHW2[FBKSzVyPUWuOFE2PTRizszN M135O3NCVkeHUh?=
NCI-H1299 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYPqb49xUUN3ME21MlQ3OzN3IN88US=> NE\IbJVUSU6JRWK=
RVH-421 NEXDNI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYrJR|UxRTVwNEm5NFgh|ryP NVK4U2p{W0GQR1XS
UM-UC-3 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlXtTWM2OD13Lk[yOlUyKM7:TR?= MoXYV2FPT0WU
MDA-MB-175-VII M1T1bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX3JR|UxRTVwNkSwOFEh|ryP MV7TRW5ITVJ?
KYSE-270 NEP3SIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVzJR|UxRTVwNk[wN|Eh|ryP MojGV2FPT0WU
COLO-668 M1O4VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV3HW4F6UUN3ME21MlcyOzJizszN NYTh[mEzW0GQR1XS
LN-405 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlrrTWM2OD13LkezNFg2KM7:TR?= M37lN3NCVkeHUh?=
HT-1376 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnPGTWM2OD13Lke4NFUzKM7:TR?= NUHtbJF6W0GQR1XS
769-P M4LKW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWr2fZMzUUN3ME21Mlg3PzF6IN88US=> MV\TRW5ITVJ?
HuP-T3 MnnYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYPSWWZuUUN3ME21Mlg5Pjd5IN88US=> MX;TRW5ITVJ?
MDA-MB-415 MkKyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mkj1TWM2OD13LkmyNVM6KM7:TR?= MX\TRW5ITVJ?
MKN7 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXTUW3lyUUN3ME21Mlk5QCEQvF2= MlTWV2FPT0WU
KS-1 M4PUemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXe2[VhVUUN3ME21Mlk5QDN4IN88US=> MXrTRW5ITVJ?
647-V NXzjc4MyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2r5T2lEPTB;NT65PVE1QCEQvF2= M2T6RXNCVkeHUh?=
COLO-679 M2HsZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1LsU2lEPTB;Nj6wNFI2PSEQvF2= M4HTSHNCVkeHUh?=
AN3-CA NXnWcYpPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NILBOoZKSzVyPU[uNFM1PDFizszN NGjVW5lUSU6JRWK=
C32 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUDkUVd1UUN3ME22MlE{ODN2IN88US=> MUnTRW5ITVJ?
KM12 NYTNb2hDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWrJR|UxRTZwMkSwPVkh|ryP MVvTRW5ITVJ?
KINGS-1 M2HZbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoW2TWM2OD14LkK2NVUzKM7:TR?= MoezV2FPT0WU
KYSE-410 NFTncJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFPjfJVKSzVyPU[uN|A3PDVizszN NFfYeWxUSU6JRWK=
HPAF-II M3PtSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2HOS2lEPTB;Nj6zOVQ5KM7:TR?= NEfmNXdUSU6JRWK=
LAN-6 M1iwNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVLJR|UxRTZwNEm2N|Eh|ryP Mlj6V2FPT0WU
LU-99A M33uSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2fzXWlEPTB;Nj61OVk5QSEQvF2= NV\lW5J[W0GQR1XS
SJSA-1 NXnvb2ZUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoPKTWM2OD14LkW2N|Q4KM7:TR?= MnPYV2FPT0WU
MSTO-211H MonoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWjRS5JIUUN3ME22MlczOjN|IN88US=> NUCzOms4W0GQR1XS
SW900 Mlv1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmW0TWM2OD14Lke2NlIyKM7:TR?= NU\IdZV7W0GQR1XS
LNCaP-Clone-FGC MknyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVXWSpBvUUN3ME22MlgxPDB|IN88US=> NITCRmtUSU6JRWK=
OMC-1 NHi0c25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2HEZ2lEPTB;Nj64OVQxOiEQvF2= Mo\YV2FPT0WU
IST-MEL1 NFjybm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1nvNWlEPTB;Nj64PVY3QSEQvF2= NYLle4FWW0GQR1XS
TE-9 Mln4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWfJR|UxRTZwOEm4OFch|ryP MUPTRW5ITVJ?
NCI-H2030 NHvSfIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFjXfGtKSzVyPU[uPVEzOjZizszN M3vZfXNCVkeHUh?=
BFTC-909 NES0c4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGK4UXZKSzVyPUeuNFA3PDFizszN MVvTRW5ITVJ?
NCI-SNU-5 NVnoTId1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2jZ[WlEPTB;Nz6wNlE2QSEQvF2= NHTmcmJUSU6JRWK=
TE-5 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIfacmVKSzVyPUeuNFI5QDFizszN MXPTRW5ITVJ?
SK-MES-1 NFnWVYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2LqeWlEPTB;Nz6wOVQzPyEQvF2= M2nabXNCVkeHUh?=
SHP-77 NFLvS|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoT5TWM2OD15LkGzPVUzKM7:TR?= MYnTRW5ITVJ?
NCI-H1623 NYf0[5RmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGrKZ5VKSzVyPUeuNVQxPzJizszN NV24WJJ6W0GQR1XS
TE-11 MlvxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEH6XnlKSzVyPUeuNVUyQDRizszN MYPTRW5ITVJ?
EKVX NIfBfFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{LkXWlEPTB;Nz6xPVI3PyEQvF2= M2H4THNCVkeHUh?=
OVCAR-3 NHvkNHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{njNGlEPTB;Nz6yNVE{OyEQvF2= NWT1VotJW0GQR1XS
C3A MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mo\STWM2OD15LkO0OVIh|ryP NXfCOWhNW0GQR1XS
CFPAC-1 M{jacmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmnqTWM2OD15LkO2NlIzKM7:TR?= M3XnVHNCVkeHUh?=
MG-63 Mn:yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUjkZXJvUUN3ME23MlQyQDR7IN88US=> MnPRV2FPT0WU
KYSE-140 NV7OfY5bT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnvhTWM2OD15LkS0NFYyKM7:TR?= MnHNV2FPT0WU
MPP-89 MnLaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXnlVlF3UUN3ME23MlU6PzJ7IN88US=> Mlm4V2FPT0WU
COLO-824 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2nVWmlEPTB;Nz63Nlg3OyEQvF2= MWLTRW5ITVJ?
SiHa NHXkPW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUnkUZdKUUN3ME23Mlg{PzB5IN88US=> NYSwO28yW0GQR1XS
SNU-387 MnnFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3fWTWlEPTB;Nz64OVM1PyEQvF2= M2i1R3NCVkeHUh?=
A172 NXrp[WJ[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXfJR|UxRTdwOE[xO|Ih|ryP MoDRV2FPT0WU
COLO-680N MlK0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWLJR|UxRTdwOUG3N{DPxE1? M1Lj[HNCVkeHUh?=
HCC1395 MlTRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{jKdWlEPTB;OD6wOVQ2OiEQvF2= M{LxWnNCVkeHUh?=
NCI-H28 MmLIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml3DTWM2OD16LkC1PVY{KM7:TR?= M4DwXnNCVkeHUh?=
LC-2-ad MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWTTRYhFUUN3ME24MlIyQTN5IN88US=> NH3Oc21USU6JRWK=
S-117 M{\lRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1L5NmlEPTB;OD6yOVM2OyEQvF2= MWPTRW5ITVJ?
NCI-H1838 Ml3HS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4GyOmlEPTB;OD6yOVc5OSEQvF2= M{DrNXNCVkeHUh?=
PANC-10-05 M3izWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkPXTWM2OD16LkO3NFQ4KM7:TR?= NFjEZ3VUSU6JRWK=
KALS-1 MnH6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml7tTWM2OD16LkWwPVI5KM7:TR?= NXfsWZJmW0GQR1XS
LS-1034 MkD3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1TVZ2lEPTB;OD61O|Q{PyEQvF2= NEfMTI9USU6JRWK=
TGBC1TKB M4PN[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHqyd5dKSzVyPUiuO|M2OzVizszN M{XEZ3NCVkeHUh?=
OE19 MmH5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFHoNY5KSzVyPUiuO|YzPjJizszN NX\x[|MxW0GQR1XS
D-502MG NHrUU41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF:4UXNKSzVyPUiuO|Y6QTRizszN MnvBV2FPT0WU
JEG-3 MnO4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHW2R4NKSzVyPUiuO|g3OThizszN MYHTRW5ITVJ?
DBTRG-05MG NVTHNndsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWfZc5pFUUN3ME24Mlg4PTZ3IN88US=> MWnTRW5ITVJ?
ME-180 NXX2[|BST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2jrPWlEPTB;OT6wOlczPSEQvF2= MojlV2FPT0WU
NCI-H1573 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoeyTWM2OD17LkGwOVMzKM7:TR?= MULTRW5ITVJ?
HCC2998 M4DrNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXPJR|UxRTlwMUO2PFEh|ryP M1j0XHNCVkeHUh?=
ACHN Ml7qS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVfJR|UxRTlwMkS5O|Uh|ryP MmLHV2FPT0WU
D-392MG NEXRUphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoLzTWM2OD17LkK1O|E2KM7:TR?= MnvWV2FPT0WU
no-11 M4PnVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MofOTWM2OD17LkK2NFI5KM7:TR?= NH\iPFZUSU6JRWK=
KLE MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGr3V3NKSzVyPUmuN|IzOzJizszN MWnTRW5ITVJ?
Calu-6 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYLJR|UxRTlwM{e1Nlgh|ryP MX7TRW5ITVJ?
LB831-BLC MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXi2c4ZuUUN3ME25MlQ2OTdzIN88US=> NH\abG9USU6JRWK=
SW684 NHvBRZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1fDSGlEPTB;OT60OlEyPiEQvF2= NVHaSGt5W0GQR1XS
SH-4 NEDFR2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYHJR|UxRTlwNEmzOlQh|ryP Ml:3V2FPT0WU
IST-MES1 M3uwVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NILofJFKSzVyPUmuOVE3PDRizszN NVfOWJU6W0GQR1XS
Saos-2 NHrOWpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGKw[nJKSzVyPUmuOVIyQTVizszN NF3MfVFUSU6JRWK=
NCI-H2087 M1jMemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlXwTWM2OD17Lk[3N|UzKM7:TR?= NI\jbppUSU6JRWK=
SCC-9 MojUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUH3fW5PUUN3ME25MlcyQDF4IN88US=> MlPNV2FPT0WU
MFE-280 MlfWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVnMUmhNUUN3ME25MlczPzh3IN88US=> NV3kRnk6W0GQR1XS
BEN M162V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHHlNnJKSzVyPUmuPFIyPTlizszN MnLVV2FPT0WU
CP50-MEL-B MlvkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVLIfGZwUUN3ME25MlkzPDN{IN88US=> NHTTV25USU6JRWK=
SK-MEL-28 M1\lO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2G3ZmlEPTB;MUCuNFE6OyEQvF2= NY\WVWY6W0GQR1XS
NCI-H2452 NY\zSGJST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmDiTWM2OD1zMD6xOkDPxE1? MWnTRW5ITVJ?
NCI-H1395 M1nPV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1L4bGlEPTB;MUCuNVc5KM7:TR?= NWn5WlQ3W0GQR1XS
NCI-H2052 MnvmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUPyUIJ7UUN3ME2xNE4yQDh{IN88US=> MVrTRW5ITVJ?
A375 M{\lT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX7uNGk3UUN3ME2xNE4zPDV{IN88US=> Mni5V2FPT0WU
HCC38 NIDEPIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXHJR|UxRTFyLkOyNkDPxE1? MoPWV2FPT0WU
LK-2 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIi5SZNKSzVyPUGwMlQzODhizszN MmHnV2FPT0WU
SF126 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH7oOXlKSzVyPUGwMlQ4OjdizszN M{XJOHNCVkeHUh?=
SK-MEL-1 Mn60S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlfHTWM2OD1zMD63PFM5KM7:TR?= M{f4c3NCVkeHUh?=
ACN NH7jcVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MW\JR|UxRTFyLki2O|kh|ryP MlqzV2FPT0WU
BB30-HNC NVvQXHdTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnHmTWM2OD1zMD64O|EyKM7:TR?= MlO3V2FPT0WU
NCI-H747 M{jDbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1jlO2lEPTB;MUCuPFc1PiEQvF2= MoHtV2FPT0WU
KYSE-150 M3\Qcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4D3eWlEPTB;MUGuNFM5PyEQvF2= MnjFV2FPT0WU
D-247MG NYjTeoRJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVvJR|UxRTFzLkGwNFkh|ryP Ml\yV2FPT0WU
BxPC-3 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{HveWlEPTB;MUGuN|c1PyEQvF2= Mo\kV2FPT0WU
SK-MEL-30 NInHRYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnfwTWM2OD1zMT60NFc6KM7:TR?= MnrjV2FPT0WU
CAS-1 NGPuRmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHzBUo1KSzVyPUGxMlQyODlizszN MYrTRW5ITVJ?
no-10 NXTIeGVxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUPJR|UxRTF{LkGyNVch|ryP NXHtUFc6W0GQR1XS
NCI-H2405 NFPnV5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn;nTWM2OD1zMj6yNFM3KM7:TR?= MojZV2FPT0WU
KGN M{\RcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NY\2TGN2UUN3ME2xNk4zQTBzIN88US=> M2PmbXNCVkeHUh?=
BB49-HNC NIC1dYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnzFTWM2OD1zMj6zPVU3KM7:TR?= MkOxV2FPT0WU
NCI-H1693 M2\Oc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MY\JR|UxRTF{LkW4NVYh|ryP MWrTRW5ITVJ?
RO82-W-1 NVnzXmpTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4\pWWlEPTB;MUOuNFY1QSEQvF2= MnPRV2FPT0WU
CAL-85-1 Mnn1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWLmb2ZwUUN3ME2xN{41Ozl7IN88US=> MWPTRW5ITVJ?
H-EMC-SS NFm5NIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3\CXGlEPTB;MUOuPVExPCEQvF2= M3jHdXNCVkeHUh?=
SW1783 M4jDe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVfiO3U6UUN3ME2xOE4zOzlzIN88US=> M1KyRnNCVkeHUh?=
LB771-HNC NWLKcmpoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXnJR|UxRTF2LkSxPUDPxE1? NUTHTnlxW0GQR1XS
HCC70 M4fpcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGS0TopKSzVyPUG0MlQzOzNizszN Mlm2V2FPT0WU
KNS-81-FD M1T2emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWTJR|UxRTF2LkewOFUh|ryP M{n1NnNCVkeHUh?=
KYSE-520 M2nuNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIHWfGpKSzVyPUG0MlkzPyEQvF2= NEfHU49USU6JRWK=
TGBC24TKB MmHvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4r6NWlEPTB;MUSuPVU{QSEQvF2= M3TQdnNCVkeHUh?=
SNB75 NE\OfW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXGwPYhbUUN3ME2xOU4xPzJ7IN88US=> NU\Ec5dnW0GQR1XS
SW872 NYXaW5RST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NW\nTVdSUUN3ME2xOU4zOjF6IN88US=> M4PkeHNCVkeHUh?=
U031 NWjCZ|g3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MULJR|UxRTF3LkiwNlgh|ryP NXHWfWZmW0GQR1XS
ChaGo-K-1 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkDlTWM2OD1zNT64N|U6KM7:TR?= Mn3DV2FPT0WU
NCI-H441 MkPES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnrFTWM2OD1zNj6wNFM6KM7:TR?= MoPxV2FPT0WU
TE-12 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlHVTWM2OD1zNj6xPFc{KM7:TR?= NIPyWI1USU6JRWK=
NCI-H1755 NUfCd|MyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkDDTWM2OD1zNj61O|Mh|ryP M{nSfHNCVkeHUh?=
KNS-42 M3TmN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkK4TWM2OD1zNj62OVg6KM7:TR?= MWLTRW5ITVJ?
SK-PN-DW MkmyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGLRTYtKSzVyPUG3MlQzODFizszN M1e0R3NCVkeHUh?=
NCI-H226 NVnPVXQzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmfMTWM2OD1zNz65N|Q2KM7:TR?= NYnYPGltW0GQR1XS
K-562 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHHxbYVKSzVyPUG4MlY{OTdizszN Mne3V2FPT0WU
A388 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIrSdW5KSzVyPUG5MlA{ODNizszN NYrxWYJwW0GQR1XS
ZR-75-30 MmKzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2S5b2lEPTB;MUmuNFk3QCEQvF2= NUSxOW1bW0GQR1XS
LU-135 NWC4T2JZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEXtTldKSzVyPUG5MlI3OzZizszN Mm\lV2FPT0WU
NCI-H2029 NULHWHhzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX3JR|UxRTF7Lk[wNlEh|ryP MlvBV2FPT0WU
HT-1197 NXXGfZhnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXHJR|UxRTF7LkmyNlch|ryP MmG3V2FPT0WU
IGR-1 MljBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVHJR|UxRTJyLkOxNVch|ryP NY\CU2RxW0GQR1XS
U-87-MG NXnXUlA2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVvJR|UxRTJyLk[0NVMh|ryP MkHNV2FPT0WU
NCI-H1304 M2PiN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmrZTWM2OD1{MD63OVAyKM7:TR?= M2fXbXNCVkeHUh?=
RCC10RGB MoPjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUThUXdDUUN3ME2yNU4zQDJ7IN88US=> NV3BfottW0GQR1XS
NCI-H520 M{nBOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3nueGlEPTB;MkKuO|YyOSEQvF2= MYfTRW5ITVJ?
SK-LU-1 MkHqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2HIRWlEPTB;MkOuNFcyQCEQvF2= NILjPXVUSU6JRWK=
UACC-893 NFPQUplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml3JTWM2OD1{Mz6xNFM5KM7:TR?= MlLvV2FPT0WU
NCI-H2347 NWfrTIQ5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV3TPXZ2UUN3ME2yN{4zPjd2IN88US=> NH35O2VUSU6JRWK=
U-118-MG MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF;6fYRKSzVyPUKzMlczOTdizszN NUDnNmpCW0GQR1XS
NCI-H596 NH;OcVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2O1bmlEPTB;MkOuPVA2PSEQvF2= MkjEV2FPT0WU
MZ1-PC M{XiNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkXrTWM2OD1{ND62O|U6KM7:TR?= MofGV2FPT0WU
SW1417 NYCyOG5[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHnLb5ZKSzVyPUK1MlI1QThizszN NXvaXpRwW0GQR1XS
NCI-H82 NYHXfYhjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVXJR|UxRTJ4LkSyPFgh|ryP NFLYdGhUSU6JRWK=
COLO-678 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlfyTWM2OD1{Nz60PVE6KM7:TR?= NFzwSoFUSU6JRWK=
KURAMOCHI MknuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWHJR|UxRTJ6LkGyOkDPxE1? MUHTRW5ITVJ?
NCI-H1650 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYf0Z|ZUUUN3ME2zNE4yQTJ2IN88US=> MmDBV2FPT0WU
HCC1954 NXTCb5dbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV32XJNTUUN3ME2zNU4{PjZ4IN88US=> NIL5ToxUSU6JRWK=
GAK NV;vTXV1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnHGTWM2OD1|Mj6yOlE3KM7:TR?= MmfEV2FPT0WU
YAPC MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHz4fmtKSzVyPUOzMlc3PDhizszN NEPyUIxUSU6JRWK=
NCI-H2228 NU[5WIJ6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2PWPWlEPTB;M{SuN|YxPSEQvF2= MoHYV2FPT0WU
VMRC-RCZ NUPLTG52T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUHuUVcyUUN3ME2zOk4{ODJ{IN88US=> M4rxcXNCVkeHUh?=
NMC-G1 NUTZSZBjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{e0[GlEPTB;M{euNFUzQSEQvF2= NYTzcmZPW0GQR1XS
D-336MG NX7B[lRGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGTnV|NKSzVyPUSxMlg1PDJizszN NHTmOVFUSU6JRWK=
UACC-62 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml:wTWM2OD12Mj61OVA2KM7:TR?= MWjTRW5ITVJ?
C-33-A MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFHY[4pKSzVyPUS1MlMzPTZizszN MlX5V2FPT0WU
HCC1937 MnfNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYTJR|UxRTR5LkG5OVgh|ryP Ml2xV2FPT0WU
HDLM-2 MmX0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXnTfXprUUN3ME20O{4zOjh5IN88US=> MXLTRW5ITVJ?
NCI-H727 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M33pXGlEPTB;NEeuNlQ2OSEQvF2= MmrhV2FPT0WU
NY M3HVPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFLaSY1KSzVyPUS5MlM6ODhizszN Ml[4V2FPT0WU
NCI-H2291 M1S4NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGXOOlJKSzVyPUS5Mlg{ODFizszN NGjwZ3RUSU6JRWK=

他の多くの細胞株試験データをご覧になる場合はこちらをクリックして下さい
アッセイ
Methods Test Index PMID
Western blot
Ac-Histone H4/Ac-Histone H3; 

PubMed: 21598070     


D54 and U87 glioma cells were treated with lower concentrations (1-3 µM) of vorinostat. The effects on histone acetylation was assessed by immunoblotting. 

phospho-CDK1; 

PubMed: 21598070     


Changes in level of inhibitory phosphorylation of cdk1 after treatment with vorinostat was determined at 24 and 48 h (using a Tyr-15 residue phospho-specific antibody) along with total cdk1 as loading control. 

phospho-Cdc25c/Cdc25c; 

PubMed: 21598070     


Time course of changes in phospho-cdc25c levels after exposure to vorinostat (5 µM).

Cyclin B1; 

PubMed: 21598070     


Cyclin B1 levels were determined in D54 and U87 cells after treatment with various doses of vorinostat at 24 and 48 h.

c-Myc/c-Raf/Akt/Cyclin D1/CDK4; 

PubMed: 19440035     


Cell lysates from JeKo-1 and Mo2058 cells exposed to vorinostat  were immunoblotted for c-Myc, c-Raf, AKT, cyclin D1, CDK4 and acetylated histone H3. The levels of β-actin served as the loading control.

p-eIF2α/ATF4/CHOP ; 

PubMed: 20072656     


Western blot was performed to evaluate activated eIF2α (P-eIF2α), translational up-regulation of ATF4, and CHOP expression in U251 cells after vorinostat exposure.

p21; 

PubMed: 21598070     


To determine the dose response relationship to vorinostat, cells were exposed to various higher concentrations (5–10 µM) of the agent and the levels of p21 determined by immunoblotting.

21598070 19440035 20072656
Immunofluorescence
HDAC1/CK19; 

PubMed: 29917299     


Immunocytochemistry to detect the expression of HDAC1 and CK 19 in PDAC cells with/without Vorinostat treatment. HDAC1 and CK19 were stained red and green, respectively. The Hoechst‐stained nuclei appear blue. Scale bar: 100 μm. The CK19 expression in PSN1 and MiaPaCa2 was increased by Vorinostat treatment.

Nrf2; 

PubMed: 20566897     


Vorinostat induced translocation of Nrf2 from cytosol to nucleus. U937 cells were treated with 2μM vorinostat for 18 hours and then cytospun. Cells were fixed and labeled for Nrf2 protein (red) and nucleus (blue, 4,6-diamidino-2-phenylindole) as described in “Immunofluorescence and confocal microscopy.” Images were taken by Nikon Eclipse TE2000 confocal microscope with 40×/1.30 numeric aperture oil objective lens. Ctrl indicates control cells without treatment; and Vor, vorinostat.

α-SMA; 

PubMed: 26330748     


Representative immunofluorescence images and the quantification graph showing the effect of vorinostat (2.5 µM), TGIF1, and TGIF2 siRNA knockdown on αSMA. Control human corneal fibroblast cultures (-TGFβ) showed no αSMA staining. Cultures treated with TGFβ1 (5 ng/ml) showed a robust αSMA staining. Vorinostat treatment markedly attenuated TGFβ-evoked αSMA staining. The knockdown of TGIF1 (+TGFβ+vorinostat+TGIF1siRNA) and TGIF2 alone (+TGFβ+vorinostat+TGIF2siRNA) or in combination (+TGFβ +vorinostat +TGIF1 +2siRNA) markedly blocked the effect of vorinostat on αSMA. Scale bar=100 μm.

Ac-STAT3/IGF2; 

PubMed: 27086926     


Immunofluorescence staining of Ac-STAT3 and IGF2 after vorinostat treatment.

29917299 20566897 26330748 27086926
Growth inhibition assay
Cell apoptosis; 

PubMed: 19440035     


Cells were treated with indicated concentrations of vorinostat for 48 hours. Following this, the percentage of annexin-V-stained apoptotic cells was determined by flow cytometry. Values represented as bar graphs are the mean of 3 experiments plus or minus the standard error (SE)

Cell viability; 

PubMed: 27086926     


The effects of vorinostat on the viability of the indicated NSCLC cell lines and their corresponding acquired VoR sublines. Cell viability was determined by the MTT assay (n = 3).

19440035 27086926
ELISA
IGF2; 

PubMed: 27086926     


Determination of vorinostat-induced IGF2 production by ELISA (n = 3). The conditioned mediums (CMs) obtained from cells treated with vorinostat (5 μM) for 2 days were used for ELISA. 

IL-13/IL-10/IL-5; 

PubMed: 18541724     


Effect of vorinostat on TH1/TH2 cytokine secretion in HL cell lines. Cells were incubated with medium or vorinostat (5 μM) for 24 hours and supernatants were examined for cytokine levels by ELISA. Each value represents a mean of 3 independent experiments done in triplicate (± SEM).

M-CSF; 

PubMed: 23042302     


Primary PyMT tumor cells were treated with SAHA (0-1000nM) for varying time points (8–48h), and supernatants were assayed by ELISA for M-CSF  secretion. *P < 0.05 and **P < 0.001 versus control treatment. 

MMP-9; 

PubMed: 23042302     


Primary PyMT tumor cells were treated with SAHA (0-1000nM) for varying time points (8–48h), and supernatants were assayed by ELISA for MMP-9 secretion. *P < 0.05 and **P < 0.001 versus control treatment. 

27086926 18541724 23042302
体内試験 Administration of Vorinostat (~100 mg/kg/day) significantly inhibits the growth of CWR22 human prostate xenografts in nude mice with tumor reductions of 78%, 97% and 97%, at doses of 25 mg/kg/day, 50 mg/kg/day and 100 mg/kg/day, respectively, compared with control. Vorinostat induces the accumulation of acetylated core histones and prostate-specific antigen mRNA expression in CWR22 cells, resulting in higher levels of serum prostate-specific antigen than predicted from tumor volume alone. [2] Oral administration of Vorinostat (0.67g/L) crosses the blood-brain barrier, increases histone acetylation in the brain, and dramatically improves the motor impairment in the R6/2 mice model of Huntington's disease. [5]

お薦めの試験操作（参考用のみ）

キナーゼ試験：

[1]
+ 展開

Immunoprecipitation-HDAC assays:

The lysate of Jurkat cells is incubated for 1 hour on ice and cleared by centrifugation at 12,000 g for 10 minutes at 4 °C. Supernatants are precleared with 30 μL of 50% protein G-Sepharose slurry for 1 hour at 4 °C. Beads are pelleted by centrifugation and supernatants are incubated for 1 hour at 4 °C with 10 μg of IgG fraction from anti-HDAC1 or HDAC3 polyclonal antisera (preincubated 2 hours at room temperature with either the homologous or heterologous immunizing peptide). Both antisera are raised in rabbits against the carboxylterminal peptide of HDAC1 and HDAC3 by using synthetic peptides coupled to keyhole limpet hemocyanin. 30 μL of 50% protein G-Sepharose slurry is added for 1 hour at 4 °C. Immune complexes are pelleted by centrifugation and washed three times with 1 mL of lysis buffer. Beads are resuspended in 200 μL of HDAC buffer (20 mM Tris-HCl, pH 8.0/150 mM NaCl/10% glycerol), and the HDAC assay is performed with an 3H-acetylated peptide corresponding to amino acids 1-24 of histone H4. Released [3H]acetic acid is quantified by scintillation counting. For inhibitions studies, the immunoprecipitated complexes are preincubated with the different concentrations of Vorinostat for 30 minutes at 4 °C.
細胞試験：

[2]
+ 展開
  • 細胞株： LNCaP, PC-3, and TSU-Pr1
  • 濃度： Dissolved in DMSO, final concentrations ~7.5 μM
  • 反応時間： 1, 2, 3 and 4 days
  • 実験の流れ：

    Cells are exposed to various concentrations of Vorinostat for 1, 2, 3 and 4 days. Cell viability is assessed by trypan blue dye exclusion.


    (参考用のみ)
動物試験：

[2]
+ 展開
  • 動物モデル： Male BALB/c nude (nu/nu) mice implanted with CWR22 tumor cells
  • 製剤： Dissolved in DMSO
  • 投薬量： ~100 mg/kg/day
  • 投与方法： Injection i.p.
    (参考用のみ)

溶解度 (25°C)

体外 DMSO 52 mg/mL (196.74 mM)
Ethanol 3 mg/mL (11.35 mM)
Water Insoluble
体内 左から（NMPから）右の順に溶剤を製品に加えます(文献ではなく、Selleckの実験によるデータ):
2% DMSO+30% PEG 300+5% Tween 80+ddH2O
混合させたのち直ちに使用することを推奨します。 		5mg/mL

* 溶解度測定はSelleck技術部門によって行われており、その他文献に示されている溶解度と差異がある可能性がありますが、同一ロットの生産工程で起きる正常な現象ですからご安心ください。

化学情報

分子量 264.3
化学式

C14H20N2O3
CAS No. 149647-78-9
保管 粉
in solvent
別名 SAHA, MK0683, suberoylanilide hydroxamic acid

便利ツール

モル濃度計算器

モル濃度計算器

求めたい質量、体積または濃度を計算してください。

質量 (g) = 濃度 (mol/L) x 体積 (L) x 分子量 (g/mol)

モル濃度計算器方程式

  • 質量
    濃度
    体積
    分子量

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとMSDS/COA（製品ページで利用可能な）。

希釈計算器

希釈計算器

貯蔵液を準備するために必要な希釈率を計算してください。Selleck希釈計算器は、以下の方程式に基づきます：

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます：C1V1 = C2V2 ( 入力 出力 )

  • C1
    V1
    C2
    V2

常に貯蔵液を準備するとき、小びんラベルとMSDS/COA（オンラインで利用できる）で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

  • 連続希釈剤

  • 計算結果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください：

総分子量：g/mol

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

質量 濃度 体積 分子量

臨床試験

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03022565 Recruiting Uveal Melanoma University of Miami|University of Miami Sylvester Comprehensive Cancer Center July 2019 Early Phase 1
NCT03022565 Recruiting Uveal Melanoma University of Miami|University of Miami Sylvester Comprehensive Cancer Center July 2019 Early Phase 1
NCT03843528 Not yet recruiting Acute Myeloid Leukemia|Myelodysplastic Syndromes|Mixed Phenotype Acute Leukemia|Juvenile Myelomonocytic Leukemia Johns Hopkins All Children''s Hospital May 1 2019 Phase 1
NCT03843528 Not yet recruiting Acute Myeloid Leukemia|Myelodysplastic Syndromes|Mixed Phenotype Acute Leukemia|Juvenile Myelomonocytic Leukemia Johns Hopkins All Children''s Hospital May 1 2019 Phase 1
NCT03742245 Not yet recruiting Breast Cancer Metastatic|Breast Cancer Jenny C. Chang MD|AstraZeneca|The Methodist Hospital System April 1 2019 Phase 1
NCT03742245 Not yet recruiting Breast Cancer Metastatic|Breast Cancer Jenny C. Chang MD|AstraZeneca|The Methodist Hospital System April 1 2019 Phase 1

技術サポート

ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

Handling Instructions

他に質問がある場合は、お気軽にお問い合わせください。

  • * 必須

よくある質問（FAQ）

  • 質問1：

    What’s the recommendation about reconstitution of the compound for in vivo animal study?

  • 回答：

    We recommend the following vehicle for S1047: 2% DMSO, 40% PEG 300, 5% Propylene glycol, 1% Tween 80 at 5 mg/mL.

selleck catalog

HDACシグナル伝達経路

HDAC Inhibitors with Unique Features

相関HDAC製品

  • LMK-235

    LMK-235 is a selective inhibitor of HDAC4 and HDAC5 with IC50 of 11.9 nM and 4.2 nM, respectively.

  • CAY10603

    CAY10603 is a potent and selective HDAC6 inhibitor with IC50 of 2 pM, >200-fold selectivity over other HDACs.

  • 4SC-202

    4SC-202 is a selective class I HDAC inhibitor with IC50 of 1.20 μM, 1.12 μM, and 0.57 μM for HDAC1, HDAC2, and HDAC3, respectively. Also displays inhibitory activity against Lysine specific demethylase 1 (LSD1). Phase 1.

  • Panobinostat (LBH589)

    Panobinostat (LBH589) is a novel broad-spectrum HDAC inhibitor with IC50 of 5 nM in a cell-free assay. Phase 3.

  • Entinostat (MS-275)

    Entinostat (MS-275) strongly inhibits HDAC1 and HDAC3 with IC50 of 0.51 μM and 1.7 μM in cell-free assays, compared with HDACs 4, 6, 8, and 10. Phase 3.

  • Trichostatin A (TSA)

    Trichostatin A (TSA) is an HDAC inhibitor with IC50 of ~1.8 nM in cell-free assays.

  • Romidepsin (FK228, Depsipeptide)

    Romidepsin (FK228, depsipeptide) is a potent HDAC1 and HDAC2 inhibitor with IC50 of 36 nM and 47 nM in cell-free assays, respectively.

    Features:More effective than other classical HDAC inhibitors such as TSA, TPX, and butyrate.

Tags: Vorinostat (SAHA, MK0683)を買う | Vorinostat (SAHA, MK0683) ic50 | Vorinostat (SAHA, MK0683)供給者 | Vorinostat (SAHA, MK0683)を購入する | Vorinostat (SAHA, MK0683)費用 | Vorinostat (SAHA, MK0683)生産者 | オーダーVorinostat (SAHA, MK0683) | Vorinostat (SAHA, MK0683)化学構造 | Vorinostat (SAHA, MK0683)分子量 | Vorinostat (SAHA, MK0683)代理店
×

大阪市内で「G20サミット」が開催されることに伴い、大阪府内で大規模な交通規制が行われる影響で、6月26日（水）から7月1日（月）までの間、下記地域へ出荷が行えなくなります。
対象地域
大阪府（全域）、兵庫県（芦屋市、尼崎市、伊丹市、西宮市）
上記地域より西の地域につきましては納期の遅延が予想されます。
また、国際便も遅延が予想されているため国内在庫がない製品の納期が一週間程度遅れる可能性がございます。
ご不便をおかけいたしますが、宜しくお願い申し上げます。

×
細胞株 試験類型 濃度 培養時間 溶剤類型 活性叙述 PMID